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ABSTRACT: Homoisoflavonoids are in the subclass of the larger family of flavonoids but have one more alkyl carbon than
flavonoids. Among them, 5,7,8-trioxygenated homoisoflavonoids have not been extensively studied for synthesis and biological
evaluation. Our current objective is to synthesize 2 5,7,8-trioxygenated chroman-4-ones and 12 5,7,8-trioxygenated
homoisoflavonoids that have been isolated from the plants Bellevalia eigii, Drimiopsis maculata, Ledebouria graminifolia, Eucomis
autumnalis, Eucomis punctata, Eucomis pallidiflora, Chionodoxa luciliae, Muscari comosum, and Dracaena cochinchinensis. For this
purpose, 1,3,4,5-tetramethoxybenzene and 4′-benzyloxy-2′,3′-dimethoxy-6′-hydroxyacetophenone were used as starting materials.
Asymmetric transfer hydrogenation using Noyori’s Ru catalyst provided 5,7,8-trioxygenated-3-benzylchroman-4-ones with R-
configuration in high yield and enantiomeric excess. By selective deprotection of homoisoflavonoids using BCl3, the total synthesis of
natural products including 10 first syntheses and three asymmetric syntheses has been completed, and three isomers of the reported
dracaeconolide B could be provided. Our research on 5,7,8-trioxygenated homoisoflavonoids would be useful for the synthesis of
related natural products and pharmacological applications.
■ INTRODUCTION
Homoisoflavonoids are a subclass of the larger family of
flavonoids, with a 16-carbon skeleton that has 1 more carbon
(C9 position) than flavonoids and isoflavonoids (Figure 1).
They have a structure including two aromatic rings and a
heterocycle containing oxygen. As some review articles dealt
with the natural origins and structures of homoisoflavonoids,
they are mainly found in Asparagaceae and Fabaceae families
and are rarely seen in Polygonaceae, Portulacaceae, Orchid-
aceae, and Gentianaceae families.1,2 Homoisoflavonoids have
been reported to have various biological activities, including
antiangiogenic, antibacterial, antimutagenic, antioxidant, and
anti-inflammatory effects.3 Initially, the structural types of
homoisoflavonoids were categorized into four scaffolds3-
benzylchroman-4-one, 3-benzylidenechroman-4-one, 3-benzyl-
3-hydroxychroman-4-one, and scillascillinsby du Toit’s
group.4 As some isolated natural products were not included
in such a category of homoisoflavonoids, the newly classified
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Figure 1. Categories of homoisoflavonoids.
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five types of homoisoflavonoids are as follows: sappanin-type,
scillascillin-type, brazilin-type, caesalpin-type, and protosappa-
nin-type (Figure 1).1
Among them, sappanin-type natural products are the most
isolated and studied. The methoxy and hydroxy groups are
mainly substituted in the A ring and the B ring, respectively. In
the A ring, naturally occurring homoisoflavonoids having
mono- to tetra-substituents have been reported so far. In
particular, we have been interested in the total synthesis and
biological activities of 5,6,7-trisubstituted homoisoflavonoids.
Naturally occurring homoisoflavonoids that contain either 5,7-
dihydroxy-6-methoxy or 7-hydroxy-5,6-dimethoxy groups in
the A ring have been synthesized by us.5,6 Cremastranone and
its synthetic analogs having the 5,6,7-trimethoxy group in the A
ring were biologically evaluated against retinal and choroidal
neovascularization as a promising drug candidate for wet age-
related macular degeneration and other neovascular eye
diseases.7−12 Moreover, we developed an enantioselective
synthesis of 5,6,7-trisubstituted homoisoflavonoids such as
cremastranone having the C3-stereogenic center, which was
confirmed to have an R-configuration, and the antiangiogenic
activity of the unnatural S-isomer was found to be more potent
than the R-isomer.13 While synthetic and medicinal chemistry
on 5,6,7-trisubstituted homoisoflavonoids were established by
us, 5,7,8-trisubstituted homoisoflavonoids have not been well
studied yet, although isolated natural products have been
reported.
Naturally occurring 5,7,8-trioxygenated homoisoflavonoids
have been isolated from the plants Bellevalia eigii, Drimiopsis
maculata, Ledebouria graminifolia, Eucomis autumnalis, Eucomis
punctata, Eucomis pallidiflora, Chionodoxa luciliae, Muscari
comosum, and Dracaena cochinchinensis (Figure 2).14−23
Punctatin is known as the representative natural product for
5,7,8-trioxygenated homoisoflavonoids, and its congeners can
be given a chemical name based on punctatin. B. eigii is a
perennial plant belonging to the family Asparagaceae,
subfamily Scilloideae. The Alali group reported the cytotoxic
activity of the natural products isolated from the bulb of this
plant.14 Among them, 5-hydroxy-7,8-dimethoxychroman-4-one
(1), 7-O-methylpunctatin (2), 7-O-methyl-3′-hydroxypuncta-
tin (3), 7-methyl-3,9-dihydropunctatin (4), 7-O-methyl-3′-
hydroxy-3,9-dihydropunctatin (5), and 7,4′-di-O-methyl-3′-
hydroxy-3,9-dihydropunctatin (6) were isolated. D. maculata
is distributed mainly in South Africa and belongs to the family
Asparagaceae, subfamily Scilloideae. The Mulholland group
isolated 7-methyl-3,9-dihydropunctatin (4) from D. maculata,
which has traditionally been used as a medicine for stomach
ailments in children.15,1615,16 Eucomis genus is a perennial bulb
of the plant belonging to the family Asparagaceae, subfamily
Scilloideae. The plants are widely distributed mainly in South
Africa. The bulbs are toxic but have been used in South Africa
as traditional medicines for urologic diseases, abdominal pain,
and as an antipyretic. The Tamm group isolated 4′-O-
methylpunctatin (9) from the bulb of E. autumnalis.17
Punctatin (8) and 3,9-dihydropunctatin (11) were isolated
from the bulbs of E. punctata, Eucomis comosa, and E.
pallidiflora.18,19 C. luciliae and M. comosum are perennial plants
distributed in Southeast Europe belonging to the family
Asparagaceae and subfamily Scilloideae. The Parrilli group
isolated punctatin (8), 3′-hydroxypunctatin (10), 3,9-dihy-
dropunctatin (11), and 4′-O-methyl-3,9-dihydropunctatin
(12) from bulbs of plants.20,21 D. cochinchinensis belongs to
the family Asparagaceae and subfamily Nolinoideae in the APG
IV system. L. graminifolia is one of the 16 species comprising
the Ledebouria genus in Botswana. Ledebouria belongs to the
family Asparagaceae, subfamily Scilloideae. The Abegza group
isolated 5,7-O-dimethyl-3,9-dihydropunctatin (13) by separat-
ing the organic extract from the bulb of this plant, which has
traditionally been widely used mainly for skin irritations,
wound dressing, sores, coughs, backaches, gastroenteritis, and
as a sedative during pregnancy.22 The Jiang group isolated
dracaeconolide B (14) from the resin of this plant, which is
called dragon’s blood, and it has traditionally been used to
treat traumatic injury, fractures, diarrhea, and dysmenorrhea.23
Although various synthetic studies of the homoisoflavonoids
have been introduced, there have been few reports toward
5,7,8-trioxygenated homoisoflavonoids except Strelisky’s syn-
thesis in 1971.24 Facile synthesis of 5,7,8-trioxygenated
homoisoflavonoids has the potential to provide a general and
expedient entry into a plethora of analogues for interesting
biological activities. Herein, we report the first synthesis of
naturally occurring and synthetic 5,7,8-trioxygenated homoiso-
flavonoids from the proper acetophenones, moreover, in an
Figure 2. Naturally occurring 5,7,8-trioxygenated chromanones and homoisoflavonoids.
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enantioselective fashion by asymmetric transfer hydrogenation
and subsequent alcohol oxidation.13,25
■ RESULTS AND DISCUSSION
The syntheses of 5,7-dihydroxy-8-methoxychroman-4-one (7)
and three homoisoflavonoids (8, 9, and 11) were studied by
Strelisky et al.24 (Scheme 1). Using the Hoesch reaction, 1,3-
bis(benzyloxy)-2,5-dimethoxybenzene was converted into the
corresponding acetophenone, and a four-step synthesis was
carried out to synthesize 7. The acetate of 3-benzylidenechro-
man-4-one was obtained by a condensation reaction using
Ac2O, and finally natural products 8, 9, and 11 were
synthesized via saponification and hydrogenation. To obtain
5,7,8-trioxygenated homoisoflavonoids with improved chem-
ical yield and reproducibility, we contemplated aldol
condensation with methoxy- and benzyl-protected chroman-
4-ones. Instead, mild and facile deprotection by BCl3 was
carried out to synthesize various 5,7-dihydroxy-8-methoxy or
5-hydroxy-7,8-dimethoxy homoisoflavonoids. Referring to
enantioselective total synthesis of cremastranone by asym-
metric transfer hydrogenation, we planned to synthesize 5,7,8-
trioxygenated homoisoflavonoids with an R-configuration
(Scheme 1).
Our synthesis of 5,7,8-trioxygenated homoisoflavonoids
commenced with the synthesis of 3-benzylidenechroman-4-
ones having 5-hydroxy-7,8-dimethoxy groups, which were
prepared from 1,2,3,5-tetramethoxybenzene 15 via 5,7,8-
trimethoxychroman-4-one 18 as shown in Scheme 2. The
acetylation of 15 provided by methylation of 3,4,5-trimethox-
yphenol was conducted using Ac2O and BF3·OEt2, and 3 equiv
of BF3·OEt2 affected simultaneous demethylation in 87% yield.
On the other hand, when 1 equiv of BF3·OEt2 was used, only
the acetyl group was introduced without demethylation.
During the removal of the methyl group, the sterically
hindered methoxy group was more easily removed among
the four methoxy groups to obtain only the desired
acetophenone 16. With the acetophenone 16 in hand, the
4H-chromen-4-one 17 was provided by treatment with
dimethylformamide-dimethyl acetal (DMF-DMA) and sub-
sequent c-HCl solution in good yield. Catalytic hydrogenation
of 17 converted it to the chroman-4-one 18. BCl3-mediated
demethylation afforded the naturally occurring chroman-4-one
1 in 85% yield, and the NMR spectral data of 1 were identical
to those reported.14 Three benzaldehydes, 4-benzyloxybenzal-
dehyde, 3-benzyloxy-4-methoxybenzaldehyde, and 3,4-bis-
(benzyloxy)benzaldehyde, were used for the condensation
with chroman-4-one 18 to provide the three benzylidene
compounds (19a−c) in 62−71% yield, respectively. Unfortu-
nately, general aldol condensation did not proceed with
chroman-4-one 1 having a free phenol group instead of 18.
Finally, the benzyl and methyl groups of the benzylidenechro-
man-4-ones 19a and 19b under BCl3-mediated conditions
were removed to provide the desired natural products 2 and 3,
respectively.
Scheme 1. Strelisky’s and Our Synthetic Approaches of 5,7,8-Trioxygenated Homoisoflavonoids
Scheme 2. Synthesis of 3-Benzylidenechroman-4-ones
Having the 5-Hydroxy-7,8-dimethoxy Groupa
aThe gray box is the reported natural product and in all other
schemes.
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With 3-benzylidenechroman-4-ones (19a−c) in hand, four
benzylchroman-4-ones, including naturally occurring homoiso-
flavonoid 13, were prepared by catalytic hydrogenation as
shown in Scheme 3. The double bond of 3-benzylidenechro-
man-4-ones (19a−c) could be hydrogenated to afford 3-
benzylchroman-4-ones (20a−c) without the removal of benzyl
groups by controlling the catalyst loading and reaction time. As
in our recent report on asymmetric transfer hydrogenation by
Noyori’s Ru catalyst,26 the 3-benzylchroman-4-one (20a−c)
was treated with 30 mol % of the (R,R)-catalyst, 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU), and formic acid to
afford (3R,4R)-3-benzylchroman-4-ols (21a−c) in excellent
yields (94−97%) and enantioselectivity (92−99% enantio-
meric excess (ee)) along with the preparation of racemic cis-3-
benzylchroman-4-ols by L-selectride reduction. Ley’s oxidation
of a secondary alcohol with tetrapropylammonium perruthen-
ate (TPAP) and N-methylmorpholine N-oxide (NMO) was
chosen as a suitable alcohol oxidation of (3R,4R)-3-
benzylchroman-4-ols (21a−c) to afford three kinds of the
corresponding (R)-3-benzylchroman-4-ones ((R)-20a−c).27
Finally, BCl3-mediated deprotection was carried out to provide
naturally occurring 4−6 through the cleavage of the C5-methyl
in the A ring and benzyl group(s) in the B ring.28
Based on the successful synthesis of 5-hydroxy-7,8-
dimethoxychroman-4-one 1, we turned to consider the desired
acetophenone for the synthesis of 5,7-dihydroxy-8-methox-
ychroman-4-one 7. Thus, the known acetophenone 23 was
used as a starting material as shown in Scheme 4, and the
hydroxy group of 23 was converted into methoxy by CH3I and
Cs2CO3, followed by selective demethylation under BCl3-
mediated conditions in which it was reported to occur
selectively at a hindered methyl ether in polymethoxyarenes.29
Two isomers 24 and 25 were generated by BCl3-mediated
demethylation, followed by the introduction of a benzyl group
on C4 to afford the desired acetophenones 26 and 23 with 72
and 20% yields, respectively. With 26 in hand, the chromen-4-
one 27 was afforded by the treatment of DMF−DMA and
subsequent c-HCl. Finally, the conversion of 27 to the
debenzylated chroman-4-one 28 by general catalytic hydro-
genation, followed by BCl3-mediated demethylation on the C5
position, provided the naturally occurring chroman-4-one 7 in
96% yield.30
For the synthesis of 5,7-dihydroxy-8-methoxy homoiso-
flavonoids, the protection of the phenol group was necessary;
otherwise, the yield of condensation was quite low. Thus, 28
was benzylated on the C7 position and condensed with four
benzaldehydes to afford the corresponding 5,7,8-trioxygenated-
3-benzylidenechroman-4-ones (29a−d) as shown in Scheme 5.
BCl3-mediated deprotection was carried out to provide
naturally occurring 5,7-dihydroxy-8-methoxy homoisoflavo-
noids (8−10) in moderate yield (42−60%). Also, 3-
benzylchroman-4-ones (30 and 31) were obtained by catalytic
hydrogenation of 29a and 29d, and both the methyl on C5 and
the benzyl on the B ring were smoothly removed by BCl3-
mediated reactions to afford two naturally occurring 3-
benzylchroman-4-ones (11 and 12).
To obtain homoisoflavonoids containing either 5-hydroxy-
7,8-dimethoxy or 5,7-dihydroxy-8-methoxy groups, it was
important to study deprotection conditions to properly remove
methyl and benzyl groups from the advanced intermediates of
5,7,8-trioxygenated homoisoflavonoids such as (R)-20a−c,
29a, and 29b, as shown in Scheme 6. BCl3 was considered an
excellent reagent for deprotection owing to its mild and site-
Scheme 3. Synthesis of 3-Benzylchroman-4-ones Having 5-
Hydroxy-7,8-dimethoxy Groups Scheme 4. Synthesis of 5,7-Dihydroxy-8-methoxychroman-
4-one
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selective conditions. Interestingly, the order and process by
which benzyl and methyl are removed could be understood
through the structural confirmation of isolated intermediates
(32a−c). In the case of phenol-deprotection of 3-benzylide-
nechroman-4-one (19a, 29a, and 29b), which was a highly
conjugated system, the benzyl group(s) was removed first
followed by methyl on the C5 position. However, slightly
lower yields resulted in the overreaction of demethylation and
instability of benzylidene derivatives. In 3-benzylchroman-4-
ones ((R)-20a and (R)-20b), on the other hand, a methyl
group neighboring the carbonyl group was first removed using
BCl3 to yield the resulting intermediates (33a and 33b) having
a hydroxy group on the C5 position, followed by the removal
of benzyl group(s) on the B ring finally to afford 4 and 5,
respectively. During BCl3-mediated deprotection of (R)-20c,
the product 6 was provided via a mixture of 33c and 33d, and
so it was concluded that the reactivity to removal of methyl
and benzyl groups was similar.
Dracaeconolide B (14), 3-(4-hydroxybenzyl)-7-hydroxy-5,8-
dimethoxychromane, is unique in having the combination of a
hydroxy at the C7 position and two methoxys on C5 and C8
positions of the homoisoflavonoid and a natural chromane
skeleton, deoxygenated chroman-4-one, compared to other
5,7,8-trioxygenated homoisoflavonoids. We undertook catalytic
hydrogenation of the previous intermediate 29a to reduce the
double bond and cleave two benzyl groups as shown in
Scheme 7. Unfortunately, the spectral data of our synthetic
compound 14 were not identical to the reported ones of 1H
and 13C NMR spectroscopies.23 We attempted to synthesize
other regioisomers of dracaeconolide B to determine whether
its structure would be corrected. 3-Benzylidenechroman-4-one
19a was converted to 5-hydroxy-7,8-dimethoxy isomer 34 by
BCl3 reaction and catalytic hydrogenation of 2. In contrast, 19a
was reduced to 3-(4-hydroxybenzyl)-5,7,8-trimethoxychro-
mane 35 in which the sterically hindered C8-methoxy group
could be cleaved predominantly under the BCl3-mediated
condition to provide the 8-hydroxy-5,7-dimethoxy isomer 36.
The structural elucidation of three different regioisomers (14,
34, and 36) was confirmed by comparison of the 1H and 13C
NMR data (Table S14) and two-dimensional (2D) NMR
spectroscopy (Figures S1−S3). The position and combination
of one hydroxy and two methoxy groups on the C5, C7, and
C8 positions of the A ring were assigned by heteronuclear
multiple bond correlation (HMBC) correlations from H-6 to
C-4a, C-5, C-7, and C-8; H2-4 to C-4a, C-5, C-6, C-8a, and C-
8; and H2-2 to C-2 and C-8a.
■ CONCLUSIONS
We have developed total syntheses of 2 naturally occurring
5,7,8-trioxygenated chroman-4-ones and 12 5,7,8-trioxygen-
ated homoisoflavonoids, including 10 synthesized for the first
time. 1,3,4,5-Tetramethoxybenzene and 4′-benzyloxy-2′,3′-
dimethoxy-6′-hydroxyacetophenone were used as starting
materials. Asymmetric transfer hydrogenation using Noyori’s
Ru catalyst provided three 5,7,8-trioxygenated homoisoflava-
nones having an R-configuration in >94% yield and >92% ee.
During BCl3-mediated deprotection, we observed that the
order in which the protecting groups are removed differs
depending on the substrate. To synthesize the 5,7,8-
trioxygenated benzylchromane dracaeconolide B, the synthesis
and structural analysis of three regioisomers were executed.
Our research on 5,7,8-trioxygenated homoisoflavonoids will be
useful for the synthesis of related natural products and drug
discovery.
■ EXPERIMENTAL SECTION
All starting materials and reagents were obtained from
commercial sources and used without further purification.
Air- and moisture-sensitive reactions were performed under
nitrogen. Flash column chromatography was performed using
silica gel 60 (230−400 mesh, Merck) with the indicated
solvents. Thin-layer chromatography (TLC) was performed
using 0.25 mm silica gel plates (Merck). 1H and 13C{1H}
NMR spectra were recorded on a Bruker 600 MHz
spectrometer as solutions in deuterochloroform (CDCl3) or
methanol-d4 (CD3OD).
1H NMR data were reported on the
order of chemical shift, multiplicity (s, singlet; d, doublet; t,
triplet; q, quartet; m, multiplet and/or multiplet resonances),
number of protons, and coupling constant (J value) in hertz
(Hz). Enantiomeric excesses were determined by high-
performance liquid chromatography (HPLC) on an Agilent
1100 using one chiral column (CHIRALPAK IA, IB, IC, ID,
IG). High-resolution mass spectra (HRMS) were recorded on
an Agilent 6530 quadrupole time-of-flight (Q-TOF) liquid
chromatography (LC)/tandem mass spectrometry (MS/MS)
system (electrospray ionization (ESI)).
1,2,3,5-Tetramethoxybenzene (15). To an N,N-dime-
thylformamide (20 mL) solution of 3,4,5-trimethoxy-phenol
(3.0 g, 16 mmol), dimethyl sulfate (4.6 mL, 49 mmol) and
Cs2CO3 (10 g, 33 mmol) were added. The reaction mixture
was refluxed for 4 h. After cooling to ambient temperature, the
reaction mixture was diluted with ethyl acetate and the organic
phase was washed with water, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:5) to afford 1,2,3,5-tetramethoxybenzene
(15) (3.2 g, 98%). 1H NMR (600 MHz, CDCl3) δ 6.15 (s,
2H), 3.84 (s, 6H), 3.78 (s, 3H), 3.78 (s, 3H). 13C{1H} NMR
Scheme 5. Synthesis of Homoisoflavonoids Having 5,7-
Dihydroxy-8-methoxy Groups
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c00932
ACS Omega 2020, 5, 11043−11057
11047
(150 MHz, CDCl3) δ 156.4, 153.8, 132.4, 91.7, 61.1, 56.2,
55.6. HRMS (ESI) m/z: [M + H]+ calcd for C10H14O4
199.0970; found, 199.0966.
1-(2-Hydroxy-3,4,6-trimethoxyphenyl)ethan-1-one
(16). To a chloroform (15 mL) solution of 1,2,3,5-
tetramethoxybenzene (15) (3.2 g, 16 mmol), acetic anhydride
(1.7 mL, 18 mmol) and BF3·OEt2 (6.9 mL, 56 mmol) were
added at 0 °C. After stirring at 70 °C for 4 h, the reaction
mixture was cooled, and ice-cold water and 5% NaOH (5 mL)
were poured into the mixture. The reaction mixture was
diluted with ethyl acetate, and the organic phase was washed
with water and brine, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. The residue was purified
by flash column chromatography (ethyl acetate/n-hexane =
1:3) to afford 1-(2-hydroxy-3,4,6-trimethoxyphenyl)ethan-1-
one (16) (3.1 g, 87%). 1H NMR (600 MHz, CDCl3) δ 13.80
(s, 1H), 5.95 (s, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.80 (s, 3H),
2.61 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3) δ 203.9,
159.2, 158.9, 158.5, 130.6, 106.4, 86.5, 60.8, 56.1, 55.7, 33.3.
Scheme 6. Sequential BCl3-Mediated Deprotection of (a) 3-Benzylidenechroman-4-one and (b) 3-Benzylchroman-4-one
Scheme 7. Synthesis of Suggested Dracaeconolide B and Its
Two Isomers
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HRMS (ESI) m/z: [M + H]+ calcd for C11H14O5 227.0919;
found, 227.0914.
5,7,8-Trimethoxy-4H-chromen-4-one (17). To a sol-
ution of 1-(2-hydroxy-3,4,6-trimethoxyphenyl)ethan-1-one
(16) (2.7 g, 12 mmol) in dimethoxyethane (DME) (30 mL)
was added N,N-dimethylformamide dimethyl acetal (4.8 mL,
36 mmol). After stirring for 24 h at 80 °C, the reaction mixture
was cooled to 0 °C and c-HCl (6 mL) was added. After stirring
for 1 h at 50 °C, the reaction mixture was diluted with ethyl
acetate and the organic phase was washed with water and brine
and dried over anhydrous Na2SO4. The solvent was removed
under reduced pressure and purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/meth-
anol = 1:1:0.1) to afford 5,7,8-trimethoxy-4H-chromen-4-one
(17) (2.2 g, 76%). 1H NMR (600 MHz, CDCl3) δ 7.70 (d,
1H, J = 5.9 Hz), 6.43 (s, 1H), 6.18 (d, 1H, J = 5.9 Hz), 3.99 (s,
3H), 3.96 (s, 3H), 3.88 (s, 3H). 13C{1H} NMR (150 MHz,
CDCl3) δ 176.9, 156.7, 156.6, 152.9, 152.4, 130.7, 114.2,
110.2, 92.7, 61.8, 56.7, 56.4. HRMS (ESI) m/z: [M + H]+
calcd for C12H12O5 237.0763; found, 237.0760.
5,7,8-Trimethoxychroman-4-one (18). 5,7,8-Trime-
thoxy-4H-chromen-4-one (17) (2.8 g, 12 mmol) and 10%
Pd/C (0.38 g, 3.5 mmol) in methanol (40 mL) were placed
under an atmosphere of hydrogen. After stirring for 1 h, the
mixture was filtered through a Celite pad. After the filtrate was
concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane/methanol = 1:1:0.1) afforded 5,7,8-trime-
thoxychroman-4-one (18) (2.6 g, 92.%). 1H NMR (600 MHz,
CDCl3) δ 6.09 (s, 1H), 4.50 (t, 2H, J = 6.4 Hz), 3.93 (s, 3H),
3.90 (s, 3H), 3.79 (s, 3H), 2.72 (t, 2H, J = 6.4 Hz). 13C{1H}
NMR (150 MHz, CDCl3) δ 189.5, 158.6, 158.1, 156.7, 130.8,
106.7, 89.3, 67.3, 61.3, 56.3, 56.1, 39.0. HRMS (ESI) m/z: [M
+ H]+ calcd for C12H14O5 239.0919; found, 239.0912.
5-Hydroxy-7,8-dimethoxychroman-4-one (1). To a
solution of 5,7,8-trimethoxychroman-4-one (18) (50 mg,
0.21 mmol) in CH2Cl2 (3 mL) was added boron trichloride
(0.62 mL, 1.0 M solution in CH2Cl2) at −78 °C. After stirring
for 1 h, the reaction mixture was diluted with CH2Cl2 and
washed with water, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/n-
hexane = 1:3) to afford 5-hydroxy-7,8-dimethoxychroman-4-
one (1) (40 mg, 85%). 1H NMR (600 MHz, CDCl3) δ 11.98
(s, 1H), 6.08 (s, 1H), 4.52 (t, 2H, J = 6.3 Hz), 3.88 (s, 2H),
3.77 (s, 2H), 2.79 (t, 2H, J = 6.3 Hz). 13C{1H} NMR (150
MHz, CDCl3) δ 196.2, 161.5, 160.3, 154.0, 129.6, 103.3, 93.1,
67.1, 61.5, 56.4, 36.8. HRMS (ESI) m/z: [M + H]+ calcd for
C11H12O5 225.0763; found, 225.0760.
(E)-3-(4′-(Benzyloxy)benzylidene)-5,7,8-trimethoxy-
chroman-4-one (19a). To a solution of 5,7,8-trimethox-
ychroman-4-one (18) (0.50 g, 2.1 mmol) in toluene (20 mL)
were added 4-benzyloxybenzaldehyde (0.67 g, 3.1 mmol) and
p-toluenesulfonic acid (36 mg, 0.21 mmol) at 0 °C. The
reaction mixture was refluxed for 12 h. After cooling to
ambient temperature, the mixture was concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/meth-
anol = 1:2:0.1) to afford (E)-3-(4′-(benzyloxy)benzylidene)-
5,7,8-trimethoxychroman-4-one (19a) (0.64 g, 71%). 1H NMR
(600 MHz, CDCl3) δ 7.69 (s, 1H), 7.43 (d, J = 7.4 Hz, 2H),
7.37 (t, 2H, J = 7.6 Hz), 7.30 (t, 1H, J = 7.3 Hz), 6.92 (d, 1H, J
= 8.4 Hz), 6.88 (dd, 1H, J = 8.4, 1.7 Hz), 6.78 (d, 1H, J = 1.7
Hz), 6.15 (s, 1H), 5.17 (s, 2H), 5.13 (d, 2H, J = 1.5 Hz), 3.93
(s, 3H), 3.92 (s, 3H), 3.92 (s, 3H), 3.78 (s, 3H). 13C{1H}
NMR (150 MHz, CDCl3) δ 179.8, 159.6, 158.4, 158.3, 155.9,
136.5, 135.9, 131.8, 130.9, 130.1, 128.7, 128.1, 127.6, 127.5,
115.0, 107.6, 90.1, 70.1, 67.9, 61.3, 56.3, 56.1. HRMS (ESI) m/
z: [M + H]+ calcd for C26H24O6 433.1651; found, 433.1650.
(E)-3-(3′,4′-Bis(benzyloxy)benzylidene)-5,7,8-trime-
thoxychroman-4-one (19b). To a solution of 5,7,8-
trimethoxychroman-4-one (18) (0.50 g, 2.1 mmol) in toluene
(20 mL) were added 3,4-bis(benzyloxy)benzaldehyde (1.0 g,
3.2 mmol) and p-toluenesulfonic acid (36 mg, 0.21 mmol) at 0
°C. The reaction mixture was refluxed for 12 h. After cooling
to ambient temperature, the mixture was concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/CH2Cl2 = 1:5) to
afford (E)-3-(3′,4′-bis(benzyloxy)benzylidene)-5,7,8-trime-
thoxychroman-4-one (19b) (0.71 g, 63%). 1H NMR (600
MHz, CDCl3) δ 7.70 (s, 1H), 7.47−7.43 (m, 4H), 7.38 (td,
4H, J = 7.5, 2.1 Hz), 7.34−7.30 (m, 2H), 6.97−6.94 (m, 1H),
6.84 (dd, 2H, J = 5.4, 1.9 Hz), 6.17 (s, 1H), 5.22 (s, 2H), 5.19
(s, 2H), 5.15 (d, 2H, J = 1.7 Hz), 3.94 (s, 3H), 3.94 (s, 3H),
3.79 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3) δ 179.9,
158.5, 158.5, 156.0, 150.1, 148.6, 137.0, 136.9, 136.1, 131.1,
130.4, 128.8, 128.7, 128.2, 128.1, 127.4, 127.4, 124.3, 116.9,
114.4, 107.8, 90.2, 71.6, 71.2, 67.9, 61.5, 56.5, 56.2. HRMS
(ESI) m/z: [M + H]+ calcd for C33H30O7 539.2070; found,
539.2067.
(E)-3-(3′-(Benzyloxy)-4′-methoxybenzylidene)-5,7,8-
trimethoxychroman-4-one (19c). To a solution of 5,7,8-
trimethoxychroman-4-one (18) (0.50 g, 2.1 mmol) in toluene
(20 mL) were added 3-(benzyloxy)-4-methoxybenzaldehyde
(0.77 g, 3.2 mmol) and p-toluenesulfonic acid (36 mg, 0.21
mmol) at 0 °C. The reaction mixture was refluxed for 13 h.
After cooling to ambient temperature, the mixture was
concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/n-
hexane/methanol = 1:2:0.1) to afford (E)-3-(3′-(benzyloxy)-
4′-methoxybenzylidene)-5,7,8-trimethoxychroman-4-one
(19c) (0.60 g, 62%). 1H NMR (600 MHz, CDCl3) δ 7.77 (s,
1H), 7.41 (d, 2H, J = 7.3 Hz), 7.37 (t, 2H, J = 7.3 Hz), 7.32 (d,
1H, J = 7.3 Hz), 7.23 (d, 2H, J = 8.7 Hz), 7.00 (d, 2H, J = 8.7
Hz), 6.16 (s, 1H), 5.28 (d, 2H, J = 1.6 Hz), 5.08 (s, 2H), 3.92
(s, 3H), 3.91 (s, 3H), 3.77 (s, 3H). 13C{1H} NMR (150 MHz,
CDCl3) δ 179.8, 158.4, 158.4, 155.9, 150.8, 147.9, 136.8,
136.1, 131.0, 130.2, 128.8, 128.1, 127.5, 127.3, 124.2, 115.9,
111.6, 107.7, 90.2, 71.2, 67.9, 61.4, 56.4, 56.1, 56.1. HRMS
(ESI) m/z: [M + H]+ calcd for C27H26O7 463.1757; found,
463.1754.
7-O-Methoxypunctatin (2). To a solution of (E)-3-(4′-
(benzyloxy)benzylidene)-5,7,8-trimethoxychroman-4-one
(19a) (31 mg, 0.07 mmol) in CH2Cl2 (2 mL) was added
boron trichloride (0.21 mL, 1.0 M solution in CH2Cl2) at −78
°C. After stirring for 1 h, the reaction mixture was diluted with
CH2Cl2, washed with water, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate/n-hexane/methanol = 1:1:0.1) to afford 7-O-methox-
ypunctatin (2) (20 mg, 85%). 1H NMR (600 MHz, CDCl3) δ
12.66 (s, 1H), 7.79 (s, 1H), 7.20 (d, 2H, J = 8.6 Hz), 6.91 (d,
2H, J = 8.6 Hz), 6.11 (s, 1H), 5.55 (s, 1H), 5.34 (d, 2H, J = 1.7
Hz), 3.88 (s, 3H), 3.76 (s, 3H). 13C{1H} NMR (150 MHz,
CDCl3) δ 185.8, 161.5, 161.1, 157.5, 153.0, 137.7, 132.5,
129.5, 127.6, 127.0, 116.1, 103.2, 93.4, 67.8, 61.6, 56.4. HRMS
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(ESI) m/z: [M + H]+ calcd for C18H16O6 329.1025; found,
329.1023.
7-O-Methyl-3′-hydroxypunctatin (3). To a solution of
(E)-3-(3′,4′-bis(benzyloxy)benzylidene)-5,7,8-trimethoxy-
chroman-4-one (19b) (31 mg, 0.06 mmol) in CH2Cl2 (2 mL)
was added boron trichloride (0.17 mL, 1.0 M solution in
CH2Cl2) at 0 °C. After stirring for 30 min, the reaction mixture
was diluted with CH2Cl2, washed with water, dried over
Na2SO4, and concentrated under reduced pressure. The
residue was purified by flash column chromatography on silica
gel (ethyl acetate/n-hexane/methanol = 1:1:0.1) to afford (E)-
3-(3,4-dihydroxybenzylidene)-5-hydroxy-7,8-dimethoxychro-
man-4-one (3) (16 mg, 83%). 1H NMR (600 MHz, CD3OD)
δ 7.72 (s, 1H), 6.89 (d, 1H, J = 8.2 Hz), 6.85 (s, 1H), 6.81 (d,
1H, J = 8.2 Hz), 6.19 (s, 1H), 5.40 (s, 1H), 3.89 (s, 1H), 3.72
(s, 1H). 13C{1H} NMR (150 MHz, CD3OD) δ 187.1, 162.9,
162.2, 154.5, 149.4, 146.8, 139.3, 130.7, 128.0, 127.5, 125.1,
118.6, 116.8, 104.1, 94.2, 69.1, 61.7, 56.9. HRMS (ESI) m/z:
[M + H]+ calcd for C18H16O7 345.0974; found, 345.0978.
5,7,8-Trimethoxy-3-(4′-hydroxybenzyl)-4-chroma-
none (13). (E)-3-(4′-(Benzyloxy)benzylidene)-5,7,8-trime-
thoxychroman-4-one (19a) (30 mg, 0.07 mmol) and 10%
Pd/C (3.7 mg, 0.03 mmol) in methanol (3 mL) were placed
under an atmosphere of hydrogen. After stirring for 2 h, the
mixture was filtered through a Celite pad. After the filtrate was
concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane/methanol = 1:2:0.1) afforded 5,7,8-trime-
thoxy-3-(4′-hydroxybenzyl)-4-chromanone (13) (22 mg,
90%). 1H NMR (600 MHz, CD3OD) δ 7.08 (d, 2H, J = 8.1
Hz), 6.76 (d, 2H, J = 8.1 Hz), 6.32 (s, 1H), 4.34 (dd, 1H, J =
11.3, 3.8 Hz), 4.18 (dd, 1H, J = 11.3, 7.1 Hz), 3.96 (s, 3H),
3.90 (s, 3H), 3.73 (s, 3H), 3.06 (dd, J = 13.8, 4.6 Hz, 1H),
2.76−2.70 (m, 1H), 2.66 (dd, 1H, J = 13.6, 10.4 Hz). 13C{1H}
NMR (150 MHz, CD3OD) δ 193.9, 160.4, 159.6, 157.4, 156.9,
131.4, 131.0, 130.2, 116.2, 106.1, 90.5, 70.1, 61.2, 56.5, 56.2,
49.7, 33.1. HRMS (ESI) m/z: [M + H]+ calcd for C19H20O6
345.1338; found, 345.1332.
3-(4′-Benzyloxy)-5,7,8-trimethoxychroman-4-one
(20a). An ethyl acetate (3 mL) and CH2Cl2 (1 mL) solution of
(E)-3-(4-(benzyloxy)-benzylidene)-5,7,8-trimethoxychroman-
4-one (19a) (27 mg, 0.06 mmol) as well as 5% wet Pd/C (3.5
mg, 0.03 mmol) was placed under an atmosphere of hydrogen.
After stirring for 1 h, the mixture was filtered through a Celite
pad. After the filtrate was concentrated under reduced
pressure, purification of the residue via flash column
chromatography on silica gel (ethyl acetate/n-hexane/meth-
anol = 1:3:0.1) afforded 3-(4′-(benzyloxy)benzyl)-5,7,8-
trimethoxychroman-4-one (20a) (25 mg, 93%). 1H NMR
(600 MHz, CDCl3) δ 7.43 (d, 2H, J = 7.3 Hz), 7.38 (t, 2H, J =
7.5 Hz), 7.32 (t, 1H, J = 7.3 Hz), 7.15 (d, 2H, J = 8.6 Hz), 6.92
(d, 2H, J = 8.6 Hz), 6.12 (s, 1H), 5.04 (s, 2H), 4.35 (dd, 1H, J
= 11.3, 4.1 Hz), 4.18 (dd, 1H, J = 11.3, 7.5 Hz), 3.94 (s, 3H),
3.92 (s, 3H), 3.79 (s, 3H), 3.19 (dd, 1H, J = 14.0, 4.4 Hz), 2.77
(m, 1H), 2.64 (dd, 1H, J = 14.0, 10.6 Hz). 13C{1H} NMR
(150 MHz, CDCl3) δ 191.7, 158.6, 158.3, 157.6, 156.4, 137.2,
130.9, 130.7, 130.3, 128.7, 128.0, 127.6, 115.1, 105.8, 89.3,
70.1, 69.3, 61.3, 56.3, 56.1, 48.7, 32.0. HRMS (ESI) m/z: [M +
H]+ calcd for C26H26O6 435.1810; found, 435.1803.
3-(3′,4′-Bis(benzyloxy)benzyl)-5,7,8-trimethoxychro-
man-4-one (20b). An ethyl acetate (9 mL) and CH2Cl2 (3
mL) solution of (E)-3-(3′,4′-bis(benzyloxy)-benzylidene)-
5,7,8-trimethoxychroman-4-one (19b) (82 mg, 0.15 mmol)
as well as 5% wet Pd/C (8.0 mg, 0.07 mmol) was placed under
an atmosphere of hydrogen. After stirring for 1 h, the mixture
was filtered through a Celite pad. After the filtrate was
concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane/methanol = 1:3:0.1) afforded 3-(3′,4′-bis-
(benzyloxy)benzyl)-5,7,8-trimethoxychroman-4-one (20b) (75
mg, 91%). 1H NMR (600 MHz, CDCl3) δ 7.47−7.43 (m, 4H),
7.38−7.34 (m, 4H), 7.33−7.28 (m, 2H), 6.87 (d, 1H, J = 8.1
Hz), 6.82 (d, 1H, J = 2.0 Hz), 6.74 (dd, 1H, J = 8.1, 2.0 Hz),
6.12 (s, 1H), 5.15 (d, 4H, J = 6.2 Hz), 4.28 (dd, 1H, J = 11.3,
4.2 Hz), 4.09 (dd, 1H, J = 11.3, 7.5 Hz), 3.94 (s, 3H), 3.92 (s,
3H), 3.80 (s, 3H), 3.15 (dd, 1H, J = 14.0, 4.3 Hz), 2.72 (m,
1H), 2.59 (dd, 1H, J = 14.0, 10.6 Hz). 13C{1H} NMR (150
MHz, CDCl3) δ 191.7, 158.6, 158.3, 156.5, 149.0, 147.8, 137.5,
137.34, 132.0, 130.7, 128.6, 127.9, 127.9, 127.6, 127.4, 122.3,
116.3, 115.5, 105.9, 89.4, 71.6, 71.5, 69.3, 61.3, 56.3, 56.2, 48.6,
32.4. HRMS (ESI) m/z: [M + H]+ calcd for C33H32O7
541.2226; found, 541.2224.
3-(3′-(Benzyloxy)-4′-methoxybenzyl)-5,7,8-trime-
thoxychroman-4-one (20c). An ethyl acetate (9 mL) and
CH2Cl2 (3 mL) solution of (E)-3-(3-(benzyloxy)-4-methox-
ybenzylidene)-5,7,8-trimethoxychroman-4-one (19c) (0.16 g,
0.35 mmol) as well as 5% wet Pd/C (18 mg, 0.17 mmol) was
placed under an atmosphere of hydrogen. After stirring for 1 h,
the mixture was filtered through a Celite pad. After the filtrate
was concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane/methanol = 1:3:0.1) afforded 3-(3′-(benzyl-
oxy)-4′-methoxybenzyl)-5,7,8-trimethoxychroman-4-one
(20c) (0.15 g, 94%). 1H NMR (600 MHz, CDCl3) δ 7.44 (d,
2H, J = 7.6 Hz), 7.35 (t, 2H, J = 7.6 Hz), 7.28 (t, 1H, J = 7.4
Hz), 6.83 (d, 1H, J = 8.1 Hz), 6.79−6.76 (m, 2H), 6.12 (s,
1H), 5.14 (s, 2H), 4.26 (dd, 1H, J = 11.3, 4.1 Hz), 4.07 (dd,
1H, J = 11.3, 7.5 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.87 (s, 3H),
3.79 (s, 3H), 3.14 (dd, 1H, J = 13.9, 4.2 Hz), 2.70 (ddd, 1H, J
= 11.6, 8.3, 4.2 Hz), 2.59 (dd, 1H, J = 13.9, 10.6 Hz). 13C{1H}
NMR (150 MHz, CDCl3) δ 191.7, 158.6, 158.3, 156.5, 148.6,
148.2, 137.2, 131.1, 130.6, 128.7, 128.0, 127.6, 122.1, 115.4,
112.1, 105.9, 89.4, 71.2, 69.3, 61.3, 56.3, 56.2, 56.2, 48.7, 32.4.
HRMS (ESI) m/z: [M + H]+ calcd for C27H28O7 465.1913;
found, 465.1909.
3-(4′-(Benzyloxy)benzyl)-5,7,8-trimethoxychroman-
4-ol ((cis)-21a). To a solution of 3-(4′-(benzyloxy)benzyl)-
5,7,8-trimethoxychroman-4-one (20a) (30 mg, 0.069 mmol) in
anhydrous tetrahydrofuran (THF) (2 mL), L-selectride (0.10
mL, 1.0 M in THF) was added dropwise at −78 °C. After 1 h,
the reaction was completed and quenched with NH4Cl,
extracted with ethyl ether, and dried over anhydrous Na2SO4.
The residue was purified by flash chromatography on silica gel
(ethyl acetate/n-hexane = 1:1) to afford 3-(4′-(benzyloxy)-
benzyl)-5,7,8-trimethoxychroman-4-ol (cis-21a) (30 mg, 98%).
(3R,4R)-3-(4′-(Benzyloxy)benzyl)-5,7,8-trimethoxy-
chroman-4-ol ((3R,4R)-21a). DBU and formic acid (3:1 (v/
v)) were dissolved in acetonitrile. The solution was sparged
with nitrogen for 15 min. Separately, 3-(4′-(benzyloxy)-
benzyl)-5,7,8-trimethoxychroman-4-one (20a) (53 mg, 0.12
mmol) and RuCl(p-cymene)[(R,R)-Ts-DPEN] (22) (23 mg,
0.036 mmol) were dissolved in acetonitrile and then added to
the mixture of DBU and formic acid. The mixture was stirred
for 24 h at 50 °C and then quenched by adding saturated
NH4Cl solution at ambient temperature. After extraction with
diethyl ether, the organic layer was washed with an additional
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portion of saturated NaHCO3 solution, dried over anhydrous
Na2SO4, and concentrated under reduced pressure. The
residue was purified by flash column chromatography on silica
gel (ethyl acetate/n-hexane/methanol = 1:1:0.1) to afford
(3R,4R)-3-(4′-(benzyloxy)benzyl)-5,7,8-trimethoxychroman-
4-ol ((3R,4R)-21a) (50 mg, 94%) [α]D
24 = +100 (c 0.10,
CH3OH). ee % = 92% ee.
1H NMR (600 MHz, CDCl3) δ 7.44
(d, 2H, J = 7.3 Hz), 7.39 (t, 2H, J = 7.5 Hz), 7.33 (t, 1H, J =
7.3 Hz), 7.20 (d, 2H, J = 8.6 Hz), 6.94 (d, 2H, J = 8.6 Hz),
6.09 (s, 1H), 5.06 (s, 2H), 4.73 (d, 1H, J = 2.5 Hz), 4.19−4.13
(m, 1H), 4.07−4.01 (m, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.77
(s, 3H), 2.90 (dd, 1H, J = 13.8, 8.4 Hz), 2.63 (dd, 1H, J = 13.8,
7.3 Hz), 2.17 (m, 1H). 13C{1H} NMR (150 MHz, CDCl3) δ
157.4, 154.2, 153.3, 149.0, 137.3, 131.9, 131.5, 130.2, 128.7,
128.1, 127.6, 115.0, 107.9, 88.6, 70.2, 65.5, 61.2, 59.9, 56.4,
55.67, 40.1, 32.0. HRMS (ESI) m/z: [M + H]+ calcd for
C26H28O6 541.2226; found, 541.2224. TR = 10 min (chiral IC,
n-hexane/EtOH = 60:40).
3-(3′,4′-Bis(benzyloxy)benzyl)-5,7,8-trimethoxychro-
man-4-ol ((cis)-21b). To a solution of 3-(3′,4′-bis-
(benzyloxy)benzyl)-5,7,8-trimethoxychroman-4-one (20b)
(30 mg, 0.056 mmol) in anhydrous THF (2 mL), L-selectride
(0.08 mL, 1.0 M in THF) was added dropwise at −78 °C.
After 1 h, the reaction was completed, quenched with saturated
NH4Cl solution, extracted with ethyl ether, and dried over
anhydrous Na2SO4. The residue was purified by flash
chromatography on silica gel (ethyl acetate/n-hexane = 1:1)
to afford 3-(3′,4′-bis(benzyloxy)benzyl)-5,7,8-trimethoxychro-
man-4-ol (cis-21b) (26 mg, 85%).
(3R,4R)-3-(3′,4′-Bis(benzyloxy)benzyl)-5,7,8-trime-
thoxychroman-4-ol ((3R,4R)-21b). DBU and formic acid
(3:1 (v/v)) were dissolved in acetonitrile. The solution was
sparged with nitrogen for 15 min. Separately, 3-(3′,4′-
bis(benzyloxy)benzyl)-5,7,8-trimethoxychroman-4-one (20b)
(30 mg, 0.06 mmol) and RuCl(p-cymene)[(R,R)-Ts-DPEN]
(22) (11 mg, 0.02 mmol) were dissolved in acetonitrile and
then added to the mixture of DBU and formic acid. The
mixture was stirred for 24 h at 50 °C and then quenched by
adding saturated NH4Cl solution at ambient temperature.
After extraction with diethyl ether, the organic layer was
washed with an additional portion of saturated NaHCO3
solution, dried over anhydrous Na2SO4, and concentrated
under reduced pressure. The residue was purified by flash
column chromatography on silica gel (ethyl acetate/n-hexane/
methanol = 1:1:0.1) to afford (3R,4R)-3-(3′,4′-bis(benzyloxy)-
benzyl)-5,7,8-trimethoxychroman-4-ol ((3R,4R)-21b) (28 mg,
94%) [α]D
24 = +103 (c 0.096, CH3OH). ee % = 95% ee.
1H
NMR (600 MHz, CDCl3) δ 7.45 (dd, 4H, J = 7.2, 1.9 Hz),
7.36 (dt, 4H, J = 15.2, 7.6 Hz), 7.30 (dd, 2H, J = 14.6, 7.3 Hz),
6.89 (d, 1H, J = 8.2 Hz), 6.87 (d, 1H, J = 2.0 Hz), 6.78 (dd,
1H, J = 8.2, 2.0 Hz), 6.09 (s, 1H), 5.14 (dd, 4H, J = 10.7, 2.7
Hz), 4.65 (s, 1H), 4.10 (ddd, 1H, J = 10.4, 3.5, 1.0 Hz), 4.03−
3.98 (m, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.78 (s, 3H), 2.83
(dd, 1H, J = 13.8, 8.5 Hz), 2.59 (dd, 1H, J = 13.8, 7.2 Hz),
2.16−2.09 (m, 1H). 13C{1H} NMR (150 MHz, CDCl3) δ
154.2, 153.3, 149.0, 147.6, 137.6, 137.5, 133.0, 131.5, 128.6,
128.6, 127.9, 127.6, 127.5, 122.2, 116.6, 115.5, 107.9, 88.6,
71.6, 71.6, 65.5, 61.2, 59.8, 56.4, 55.7, 40.0, 32.4. HRMS (ESI)
m/z: [M + Na]+ calcd for C33H34O7 565.2202; found,
565.2204. TR = 30 min (chiral ID, n-hexane/IPA/EtOH =
60:20:20).
3-(3′-(Benzyloxy)-4′-methoxybenzyl)-5,7,8-trime-
thoxychroman-4-ol ((cis)-21c). To a solution of 3-(3′-
(benzyloxy)-4′-methoxybenzyl)-5,7,8-trimethoxychroman-4-
one (20c) (30 mg, 0.065 mmol) in anhydrous THF (2 mL), L-
selectride (0.10 mL, 1.0 M in THF) was added dropwise at
−78 °C. After 1 h, the reaction was completed and quenched
with NH4Cl, extracted with ethyl ether, and dried over
anhydrous Na2SO4. The residue was purified by flash
chromatography on silica gel (ethyl acetate/n-hexane = 1:1)
to afford 3-(3′-(benzyloxy)-4′-methoxybenzyl)-5,7,8-trime-
thoxychroman-4-ol (cis-21c) (30 mg, 99%).
(3R,4R)-3-(3′-(Benzyloxy)-4′-methoxybenzyl)-5,7,8-
trimethoxychroman-4-ol ((3R,4R)-21c). DBU and formic
acid (3:1 (v/v)) were dissolved in acetonitrile. The solution
was sparged with nitrogen for 15 min. Separately, 3-(3′-
(benzyloxy)-4′-methoxybenzyl)-5,7,8-trimethoxychroman-4-
one (20c) (86 mg, 0.19 mmol) and RuCl(p-cymene)[(R,R)-
Ts-DPEN] (22) (35 mg, 0.06 mmol) were dissolved in
acetonitrile and then added to the mixture of DBU and formic
acid. The mixture was stirred for 24 h at 50 °C and then
quenched by adding saturated NH4Cl solution at ambient
temperature. After extraction with diethyl ether, the organic
layer was washed with an additional portion of saturated
NaHCO3 solution, dried over Na2SO4, and concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/meth-
anol = 1:1:0.1) to afford (3R,4R)-3-(3′-(benzyloxy)-4′-
methoxybenzyl)-5,7,8-trimethoxy-chroman-4-ol ((3R,4R)-
21c) (84 mg, 97%) [α]D
24 = +92 (c 0.098, CH3OH). ee % =
99% ee. 1H NMR (600 MHz, CDCl3) δ 7.44 (d, 2H, J = 7.3
Hz), 7.35 (t, 2H, J = 7.6 Hz), 7.29−7.25 (m, 1H), 6.86−6.81
(m, 3H), 6.08 (s, 1H), 5.14 (s, 2H), 4.63 (d, 1H, J = 2.8 Hz),
4.11−4.07 (m, 1H), 4.02−3.97 (m, 1H), 3.88 (s, 3H), 3.86 (s,
3H), 3.81 (s, 3H), 3.78 (s, 3H), 2.81 (dd, 1H, J = 13.8, 8.6
Hz), 2.58 (dd, 1H, J = 13.8, 7.2 Hz), 2.15−2.08 (m, 1H).
13C{1H} NMR (150 MHz, CDCl3) δ 154.2, 153.3, 148.91,
148.3, 148.1, 137.4, 132.0, 131.5, 128.6, 127.9, 127.5, 121.9,
115.6, 112.1, 107.8, 88.5, 71.2, 65.5, 61.1, 59.8, 56.4, 56.2, 55.6,
40.0, 32.3. HRMS (ESI) m/z: [M + H]+ calcd for C27H30O7
497.2070; found, 467.2063. TR = 26 min (chiral ID, n-hexane/
IPA/EtOH = 60:20:20).
(R)-3-(4′-(Benzyloxy)benzyl)-5,7,8-trimethoxychro-
man-4-one ((R)-20a). A solution of (3R,4R)-3-(4′-
(benzyloxy)benzyl)-5,7,8-trimethoxychroman-4-ol ((3R,4R)-
21a) (0.11 g, 0.24 mmol) in CH2Cl2 (5 mL) was treated
with molecular sieves (4 Å, 0.10 g) and N-methylmorpholine
N-oxide (0.1 g, 0.84 mmol), and the mixture was stirred for 15
min. Then, tetrapropylammonium perruthenate (85 mg, 0.24
mmol) was added, and stirring was continued at ambient
temperature for 30 min. The reaction mixture was diluted with
diethyl ether, washed with water, dried over anhydrous
Na2SO4, and concentrated under reduced pressure. The
residue was purified by flash column chromatography on silica
gel (ethyl acetate/n-hexane = 1:3) to afford (R)-3-(4′-
(benzyloxy)benzyl)-5,7,8-trimethoxychroman-4-one ((R)-
20a) (0.10 g, 97%) [α]D
24 = −83 (c 0.072, CH3OH). ee % =
92% ee. 1H NMR (600 MHz, CDCl3) δ 7.43 (d, 2H, J = 7.3
Hz), 7.38 (t, 2H, J = 7.5 Hz), 7.32 (t, 1H, J = 7.3 Hz), 7.15 (d,
2H, J = 8.6 Hz), 6.92 (d, 2H, J = 8.6 Hz), 6.12 (s, 1H), 5.05 (s,
2H), 4.35 (dd, 1H, J = 11.3, 4.1 Hz), 4.18 (dd, 1H, J = 11.3,
7.5 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.79 (s, 3H), 3.19 (dd, 1H,
J = 14.0, 4.3 Hz), 2.77 (m, 1H), 2.64 (dd, 1H, J = 14.0, 10.6
Hz). 13C{1H} NMR (150 MHz, CDCl3) δ 191.7, 158.6, 158.3,
157.6, 156.4, 137.2, 130.9, 130.7, 130.3, 128.7, 128.1, 127.6,
115.1, 105.8, 89.4, 70.2, 69.3, 61.3, 56.3, 56.2, 48.7, 32.0.
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HRMS (ESI) m/z: [M + H]+ calcd for C26H26O6 435.1808;
found, 435.1803. TR = 21 min (chiral ID, n-hexane/EtOH =
70:30).
(R)-3-(3′,4′-Bis(benzyloxy)benzyl)-5,7,8-trimethoxy-
chroman-4-one ((R)-20b). A solution of (3R,4R)-3-(3′,4′-
bis(benzyloxy)benzyl)-5,7,8-trimethoxychroman-4-ol
((3R,4R)-21b) (17 mg, 0.03 mmol) in CH2Cl2 (2 mL) was
treated with molecular sieves (4 Å, 13 mg) and N-
methylmorpholine N-oxide (13 mg, 0.11 mmol), and the
mixture was stirred for 15 min. Then, tetrapropylammonium
perruthenate (11 mg, 0.03 mmol) was added, and stirring was
continued at ambient temperature for 30 min. The reaction
mixture was diluted with diethyl ether, washed with water,
dried over anhydrous Na2SO4, and concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane = 1:3) to
afford (R)-3-(3′,4′-bis(benzyloxy)benzyl)-5,7,8-trimethoxy-
chroman-4-one ((R)-20b) (69 mg, 93%) [α]D
24 = −87 (c
0.058, CH3OH). ee % = 87% ee.
1H NMR (600 MHz, CDCl3)
δ 7.44 (dd, 4H, J = 7.1, 4.1 Hz), 7.35 (td, 4H, J = 7.5, 2.5 Hz),
7.30 (td, 2H, J = 7.2, 5.5 Hz), 6.86 (d, 1H, J = 8.2 Hz), 6.82 (d,
1H, J = 1.9 Hz), 6.74 (dd, 1H, J = 8.2, 1.9 Hz), 6.12 (s, 1H),
5.15 (s, 2H), 5.13 (s, 2H), 4.27 (dd, 1H, J = 11.3, 4.1 Hz), 4.08
(dd, 1H, J = 11.3, 7.5 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.79 (s,
3H), 3.14 (dd, 1H, J = 14.0, 4.3 Hz), 2.71 (m, 1H), 2.59 (dd,
1H, J = 14.0, 10.6 Hz). 13C{1H} NMR (150 MHz, CDCl3) δ
191.7, 158.6, 158.3, 156.4, 149.0, 147.8, 137.5, 137.3, 132.0,
130.7, 128.6, 127.9, 127.9, 127.6, 127.4, 122.3, 116.3, 115.5,
105.9, 89.3, 71.6, 71.5, 69.3, 61.3, 56.3, 56.2, 48.6, 32.4. HRMS
(ESI) m/z: [M + H]+ calcd for C33H32O7 541.2226; found,
541.2222. TR = 27 min (chiral ID, n-hexane/EtOH = 70:40).
(R)-3-(3′-(Benzyloxy)-4′-methoxybenzyl)-5,7,8-trime-
thoxychroman-4-one ((R)-20c). A solution of (3R,4R)-3-
(3′-(benzyloxy)-4′-methoxybenzyl)-5,7,8-trimethoxy-chro-
man-4-ol ((3R,4R)-21c) (70 mg, 0.15 mmol) in CH2Cl2 (3
mL) was treated with molecular sieves (4 Å, 60 mg) and N-
methylmorpholine N-oxide (60 mg, 0.51 mmol), and the
mixture was stirred for 15 min. Then, tetrapropylammonium
perruthenate (54 mg, 0.15 mmol) was added, and stirring was
continued at ambient temperature for 20 min. The reaction
mixture was diluted with diethyl ether, washed with water,
dried over anhydrous Na2SO4, and concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane = 1:3) to
afford (R)-3-(3′-(benzyloxy)-4′-methoxybenzyl)-5,7,8-trime-
thoxychroman-4-one ((R)-20c) (69 mg, 99%) [α]D
24 = −57
(c 0.088, CH3OH). ee % = 84% ee.
1H NMR (600 MHz,
CDCl3) δ 7.43 (d, 2H, J = 7.5 Hz), 7.34 (t, 2H, J = 7.5 Hz),
7.29−7.25 (m, 1H), 6.82 (d, 1H, J = 7.9 Hz), 6.77 (m, 2H),
6.11 (s, 1H), 5.12 (s, 2H), 4.25 (dd, 1H, J = 11.2, 3.7 Hz), 4.06
(dd, 1H, J = 11.2, 7.7 Hz), 3.93 (s, 3H), 3.90 (s, 3H), 3.85 (s,
3H), 3.78 (s, 3H), 3.76−3.76 (m, 1H), 3.12 (dd, 1H, J = 13.6,
3.8 Hz), 2.69 (m, 1H), 2.58 (dd, 1H, J = 13.6 10.9 Hz).
13C{1H} NMR (150 MHz, CDCl3) δ 191.6, 158.6, 158.3,
156.4, 148.5, 148.1, 137.1, 131.0, 130.6, 128.6, 127.9, 12 127.5,
122.0, 115.3, 112.0, 105.8, 89.3, 71.1, 69.2, 61.3, 56.3, 56.2,
56.1, 48.6, 32.4. HRMS (ESI) m/z: [M + H]+ calcd for
C27H28O7 465.1913; found, 465.1908. TR = 24 min (chiral ID,
n-hexane/EtOH = 70:40).
(R)-7-Methyl-3,9-dihydropunctatin ((R)-4). To a sol-
ution of (R)-3-(4-(benzyloxy)benzyl)-5,7,8-trimethoxychro-
man-4-one ((R)-20a) (32 mg, 0.08 mmol) in CH2Cl2 (2
mL) was added boron trichloride (0.23 mL, 1.0 M solution in
CH2Cl2) at −78 °C. After stirring for 40 min, the reaction
mixture was diluted with CH2Cl2, washed with water, dried
over anhydrous Na2SO4, and concentrated under reduced
pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/meth-
anol = 1:1:0.1) to afford (R)-7-methyl-3,9-dihydropunctation
((R)-4) (23 mg, 93%). [α]D
24 = −74 (c 0.068, CH3OH). ee % =
86% ee. 1H NMR (600 MHz, CD3OD) δ 7.03 (d, 2H, J = 8.5
Hz), 6.70 (d, 2H, J = 8.5 Hz), 6.13 (s, 1H), 4.29 (dd, 1H, J =
11.4, 4.3 Hz), 4.14 (dd, 1H, J = 11.4, 7.3 Hz), 3.84 (s, 3H),
3.66 (s, 3H), 3.08 (dd, 1H, J = 14.0, 4.7 Hz), 2.83 (m, 1H),
2.64 (dd, 1H, J = 14.0, 10.1 Hz). 13C{1H} NMR (150 MHz,
CD3OD) δ 199.8, 162.5, 161.3, 157.1, 154.9, 131.0, 130.2,
129.8, 116.2, 103.1, 93.6, 70.4, 61.3, 56.5, 48.0, 32.7. HRMS
(ESI) m/z: [M + H]+ calcd for C18H18O6 331.1181; found,
331.1181. TR = 7.7 min (chiral IB, 0.1% diethanolamine
(DEA) in n-hexane/EtOH = 70:30).
(R)-7-O-Methyl-3′-hydroxy-3,9-dihydropunctatin ((R)-
5). To a solution of (R)-3-(3,4-bis(benzyloxy)benzyl)-5,7,8-
trimethoxychroman-4-one ((R)-20b) (30 mg, 0.06 mmol) in
CH2Cl2 (3 mL) was added boron trichloride (0.16 mL, 1.0 M
solution in CH2Cl2) at −78 °C. After stirring for 90 min, the
reaction mixture was diluted with CH2Cl2, washed with water,
dried over anhydrous Na2SO4, and concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/meth-
anol = 1:1:0.1) to afford (R)-7-O-methyl-3′-hydroxy-3,9-
dihydropunctatin ((R)-5) (17 mg, 89%). [α]D
24 = −75 (c
0.066, CH3OH). ee % = 95% ee.
1H NMR (600 MHz, CDCl3)
δ 12.02 (s, 1H), 6.78 (d, 1H, J = 8.0 Hz), 6.73 (d, 1H, J = 2.0
Hz), 6.63 (dd, 1H, J = 8.0, 2.0 Hz), 6.08 (s, 1H), 5.54 (br s,
1H), 5.43 (br s, 1H), 4.32 (dd, 1H, J = 11.4, 4.2 Hz), 4.17 (dd,
1H, J = 11.5, 6.9 Hz), 3.87 (s, 3H), 3.76 (s, 3H), 3.08 (dd, 1H,
J = 14.0, 4.6 Hz), 2.79 (m, 1H), 2.65 (dd, 1H, J = 14.0, 10.3
Hz). 13C{1H} NMR (150 MHz, CDCl3) δ 198.4, 161.5, 160.5,
153.8, 144.0, 142.6, 130.8, 129.4, 121.8, 116.3, 115.7, 102.5,
93.2, 69.5, 61.6, 56.4, 47.0, 32.4. HRMS (ESI) m/z: [M + H]+
calcd for C18H18O7 347.1131; found, 347.1125. TR = 26 min
(chiral IG, 0.1% trifluoroacetic acid (TFA) in n-hexane/EtOH
= 70:30).
(R)-7,4′-Di-O-methyl-3′-hydroxy-3,9-dihydropuncta-
tin ((R)-6). To a solution of (R)-3-(3-(benzyloxy)-4-
methoxybenzyl)-5,7,8-trimethoxy-chroman-4-one ((R)-20c)
(25 mg, 0.05 mmol) in CH2Cl2 (2 mL) was added boron
trichloride (0.16 mL, 1.0 M solution in CH2Cl2) at −78 °C.
After stirring for 1 h, the reaction mixture was diluted with
CH2Cl2, washed with water, dried over Na2SO4, and
concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/n-
hexane/methanol = 1:1:0.1) to afford (R)-7,4′-di-O-methyl-3′-
hydroxy-3,9-dihydropunctatin ((R)-6) (18 mg, 93%). [α]D
24 =
−48 (c 0.10, CH3OH). ee % = 75% ee. 1H NMR (600 MHz,
CDCl3) δ 12.04 (s, 1H), 6.80 (d, 1H, J = 2.1 Hz), 6.78 (d, 1H,
J = 8.2 Hz), 6.69 (dd, 1H, J = 8.2, 2.1 Hz), 6.09 (s, 1H), 5.62
(s, 1H), 4.34 (dd, 1H, J = 11.4, 4.3 Hz), 4.19 (dd, 1H, J = 11.4,
7.3 Hz), 3.88 (s, 3H), 3.87 (s, 3H), 3.76 (s, 3H), 3.15 (dd, 1H,
J = 14.0, 4.6 Hz), 2.87−2.82 (m, 1H), 2.67 (dd, 1H, J = 14.0,
10.4 Hz). 13C{1H} NMR (150 MHz, CDCl3) δ 198.3, 161.5,
160.4, 153.9, 145.9, 145.6, 131.1, 129.5, 120.8, 115.3, 110.9,
102.5, 93.2, 69.5, 61.5, 56.4, 56.2, 47.0, 32.3. HRMS (ESI) m/
z: [M + H]+ calcd for C19H20O7 361.1287; found, 361.1283.
TR = 12 min (chiral IB, 0.1% diethanolamine (DEA) in n-
hexane/EtOH = 70:30).
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c00932
ACS Omega 2020, 5, 11043−11057
11052
1-(4-(Benzyloxy)-2-hydroxy-3,6-dimethoxyphenyl)-
ethan-1-one (26). First step: To an acetone (20 mL)
solution of 1-(4-(benzyloxy)-6-hydroxy-2,3-dimethoxyphenyl)-
ethan-1-one (23) (2.0 g, 6.6 mmol), 2.0 M in t-butyl methyl
ether of solution iodomethane (3.6 mL, 7.3 mmol) and
Cs2CO3 (4.3 g, 13 mmol) were added. The reaction mixture
was refluxed for 12 h. After cooling to ambient temperature,
the reaction mixture was diluted with ethyl acetate and the
organic phase was washed with water and saturated NH4Cl
solution, dried over anhydrous Na2SO4, and concentrated
under reduced pressure. The residue was purified by flash
column chromatography on silica gel (ethyl acetate/n-hexane
= 1:3) to afford 1-(4-(benzyloxy)-2,3,6-trimethoxyphenyl)-
ethan-1-one (2.0 g, 95%). 1H NMR (600 MHz, CDCl3) δ 7.44
(d, J = 7.2 Hz, 2H), 7.39 (t, J = 7.3 Hz, 2H), 7.34 (d, J = 7.1
Hz, 1H), 6.29 (s, 1H), 5.14 (s, 2H), 3.90 (s, 3H), 3.83 (s, 3H),
3.71 (s, 3H), 2.47 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3)
δ 201.4, 154.0, 152.5, 151.4, 136.9, 136.7, 128.8, 128.3, 127.4,
119.1, 94.7, 71.4, 62.2, 61.3, 56.2, 32.7. HRMS (ESI) m/z: [M
+ H]+ calcd for C18H20O5 317.1389; found, 317.1384. Second
step: To a so lut ion of 1-(4-(benzy loxy)-2 ,3 ,6-
trimethoxyphenyl)ethan-1-one (1.1 g, 5.4 mmol) in CH2Cl2
(20 mL) was added boron trichloride (16 mL, 1.0 M solution
in CH2Cl2) at −78 °C. After stirring for 1 h, the reaction
mixture was diluted with CH2Cl2, washed with water, dried
over anhydrous Na2SO4, and concentrated under reduced
pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/meth-
anol = 1:5) to afford intermediates (24 and 25) (1.0 g, 90%).
Third step: To an acetone (20 mL) solution of intermediates
(24 and 25) (1.0 g, 4.8 mmol), benzyl bromide (0.6 mL, 5.3
mmol) and K2CO3 (1.3 g, 9.6 mmol) were added. The
reaction mixture was refluxed for 2 h. After cooling to ambient
temperature, the reaction mixture was diluted with ethyl
acetate and the organic phase was washed with water and
saturated NH4Cl solution, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/n-
hexane = 1:2) to afford 1-(4-(benzyloxy)-2-hydroxy-3,6-
dimethoxyphenyl)ethan-1-one (26) (1.0 g, 72%). 1H NMR
(600 MHz, CDCl3) δ 13.82 (s, 1H), 7.43 (d, J = 7.4 Hz, 2H),
7.39 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.3 Hz, 1H), 5.97 (s, 1H),
5.22 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 2.59 (s, 3H). 13C{1H}
NMR (150 MHz, CDCl3) δ 203.9, 159.2, 158.8, 157.6, 136.4,
131.2, 128.8, 128.3, 127.3, 106.6, 88.6, 70.9, 60.9, 55.6, 33.3.
HRMS (ESI) m/z: [M + H]+ calcd for C17H18O5 303.1232;
found, 303.1227.
7-(Benzyloxy)-5,8-dimethoxy-4H-chromen-4-one
(27). To a solution of 1-(4-(benzyloxy)-2-hydroxy-3,6-
dimethoxyphenyl)ethan-1-one (26) (1.0 g, 3.3 mmol) in
DME (20 mL) was added N,N-dimethylformamide dimethyl
acetal (1.3 mL, 9.9 mmol). After stirring for 24 h at 80 °C, the
mixture was cooled to 0 °C and c-HCl (5 mL) was added.
After stirring for 1 h at 50 °C, the reaction mixture was diluted
with ethyl acetate and the organic phase was washed with
water and brine and dried over anhydrous Na2SO4. The
solvent was removed under reduced pressure and purified by
flash column chromatography on silica gel (ethyl acetate/
CH2Cl2 = 1:3) to afford 7-(benzyloxy)-5,8-dimethoxy-4H-
chromen-4-one (27) (0.97 g, 94%). 1H NMR (600 MHz,
CDCl3) δ 7.69 (d, 1H, J = 5.9 Hz), 7.45 (d, 2H, J = 7.4 Hz),
7.40 (t, 2H, J = 7.4 Hz), 7.35 (t, 1H, J = 7.3 Hz), 6.45 (s, 1H),
6.17 (d, 1H, J = 5.9 Hz), 5.26 (s, 2H), 3.90 (s, 3H), 3.86 (s,
3H). 13C{1H} NMR (150 MHz, CDCl3) δ 176.9, 156.3, 155.6,
152.9, 152.5, 136.1, 131.2, 128.9, 128.6, 127.4, 114.2, 110.5,
94.7, 71.4, 61.8, 56.6. HRMS (ESI) m/z: [M + H]+ calcd for
C18H16O5 313.1076; found, 313.1071.
7-Hydroxy-5,8-dimethoxychroman-4-one (28). 7-
(Benzyloxy)-5,8-dimethoxy-4H-chromen-4-one (27) (0.30 g,
0.96 mmol) and 10% Pd/C (0.01 g, 0.10 mmol) in anhydrous
methanol (15 mL) were placed under an atmosphere of
hydrogen. After stirring for 4 h, the mixture was filtered
through a Celite pad. After the filtrate was concentrated under
reduced pressure, purification of the residue via flash column
chromatography on silica gel (ethyl acetate/CH2Cl2 = 1:3)
afforded 7-hydroxy-5,8-dimethoxychroman-4-one (28) (0.22 g,
99%). 1H NMR (600 MHz, CD3OD) δ 6.13 (s, 1H), 4.48 (t,
2H, J = 6.4 Hz), 3.78 (s, 3H), 3.74 (s, 3H), 2.69 (t, 2H, J = 6.4
Hz). 13C{1H} NMR (150 MHz, CD3OD) δ 191.9, 159.6,
159.3, 158.6, 130.6, 106.4, 94.0, 68.1, 61.3, 56.1, 39.5. HRMS
(ESI) m/z: [M + H]+ calcd for C11H12O5 225.0763; found,
225.0759.
5,7-Dihydroxy-8-methoxychroman-4-one (7). To a
solution of 7-hydroxy-5,8-dimethoxy-chroman-4-one (28)
(30 mg, 0.13 mmol) in CH2Cl2 (3 mL) was added boron
trichloride (0.4 mL, 1.0 M solution in CH2Cl2) at −78 °C.
After stirring for 1 h, the reaction mixture was diluted with
CH2Cl2, washed with water, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:3) to afford 5,7-dihydroxy-8-methox-
ychroman-4-one (7) (27 mg, 96%). 1H NMR (600 MHz,
dimethyl sulfoxide (DMSO)-d6) δ 11.95 (s, 1H), 10.64 (s,
1H), 5.93 (s, 1H), 4.49 (t, 2H, J = 6.4 Hz), 3.62 (s, 3H), 2.77
(t, 2H, J = 6.4 Hz). 13C{1H} NMR (150 MHz, DMSO-d6) δ
196.4, 159.8, 158.7, 154.6, 128.3, 102.1, 95.7, 66.7, 60.4, 35.9.
HRMS (ESI) m/z: [M + H]+ calcd for C10H10O5 211.0606;
found, 211.0601.
7-(Benzyloxy)-5,8-dimethoxychroman-4-one. To an
acetone (10 mL) solution of 7-hydroxy-5,8-dimethoxychro-
man-4-one (28) (0.21 g, 0.94 mmol), benzyl bromide (0.1 mL,
1.0 mmol) and K2CO3 (0.39 g, 2.8 mmol) were added. The
reaction mixture was refluxed for 48 h. After cooling to
ambient temperature, the reaction mixture was diluted with
ethyl acetate and the organic phase was washed with water and
saturated NH4Cl solution, dried over anhydrous Na2SO4, and
concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/n-
hexane = 1:1) to afford 7-(benzyloxy)-5,8-dimethoxychroman-
4-one (0.25 g, 85%). 1H NMR (600 MHz, CDCl3) δ 7.42 (d,
2H, J = 7.3 Hz), 7.38 (m, 2H), 7.32 (m, 1H), 6.12 (s, 1H),
5.20 (s, 2H), 4.50 (t, 2H, J = 6.4 Hz), 3.81 (s, 3H), 3.79 (s,
3H), 2.71 (t, 2H, J = 6.4 Hz). 13C{1H} NMR (150 MHz,
CDCl3) δ 189.4, 157.8, 157.7, 156.8, 136.2, 131.3, 128.8,
128.4, 127.3, 106.9, 91.2, 70.9, 67.2, 61.3, 56.2, 38.9. HRMS
(ESI) m/z: [M + H]+ calcd for C18H18O5 315.1232; found,
315.1230.
(E)-7-(Benzyloxy)-3-(4′-(benzyloxy)benzylidene)-5,8-
dimethoxychroman-4-one (29a). To a solution of 7-
(benzyloxy)-5,8-dimethoxychroman-4-one (0.10 g, 0.32
mmol) in toluene (8 mL) were added 4-benzyloxybenzalde-
hyde (0.11 g, 0.49 mmol) and p-toluenesulfonic acid (5.5 mg,
0.03 mmol) at 0 °C. The reaction mixture was refluxed for 12
h. After cooling to ambient temperature, the mixture was
concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/
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CH2Cl2 = 1:3) to afford (E)-7-(benzyloxy)-3-(4′-(benzyloxy)-
benzylidene)-5,8-dimethoxychroman-4-one (29a) (69 mg,
43%). 1H NMR (600 MHz, CDCl3) δ 7.78 (s, 1H), 7.44 (d,
4H, J = 7.8 Hz), 7.40−7.39 (m, 4H), 7.34−7.33 (m, 2H), 7.25
(d, 2H, J = 8.7 Hz), 7.02 (d, 2H, J = 8.7 Hz), 6.20 (s, 1H),
5.31 (d, 2H, J = 1.6 Hz), 5.23 (s, 2H), 5.11 (s, 2H), 3.84 (s,
3H), 3.81 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3) δ 180.0,
159.7, 158.2, 157.6, 156.2, 136.6, 136.3, 136.1, 131.9, 131.6,
130.2, 128.9, 128.8, 128.4, 128.3, 127.7, 127.6, 127.4, 115.2,
108.1, 92.2, 71.1, 70.2, 68.1, 61.5, 56.4. HRMS (ESI) m/z: [M
+ H]+ calcd for C32H28O6 509.1964; found, 509.1961.
( E ) - 7 - ( B e n z y l o x y ) - 5 , 8 - d im e t h o x y - 3 - ( 4 ′ -
methoxybenzylidene)chroman-4-one (29b). To a solu-
tion of 7-(benzyloxy)-5,8-dimethoxychroman-4-one (50 mg,
0.16 mmol) in toluene (5 mL) were added 4-methoxybenzal-
dehyde (0.03 mL, 0.24 mmol) and p-toluenesulfonic acid (2.8
mg, 0.02 mmol) at 0 °C. The reaction mixture was refluxed for
12 h. After cooling to ambient temperature, the mixture was
concentrated under reduced pressure. The residue was purified
by flash column chromatography on silica gel (ethyl acetate/
CH2Cl2 = 1:5) to afford (E)-7-(benzyloxy)-5,8-dimethoxy-3-
(4′-methoxybenzylidene)chroman-4-one (29b) (34 mg, 49%).
1H NMR (600 MHz, CDCl3) δ 7.78 (s, 1H), 7.44 (d, 2H, J =
7.3 Hz), 7.41−7.39 (m, 2H), 7.35−7.33 (m, 1H), 7.26−7.25
(m, 2H), 6.95 (d, 2H, J = 8.7 Hz), 6.20 (s, 1H), 5.31 (d, 1H, J
= 1.7 Hz), 5.23 (s, 1H), 3.85 (s, 1H), 3.85 (s, 1H), 3.81 (s,
1H). 13C{1H} NMR (150 MHz, CDCl3) δ 180.1, 160.6, 158.2,
157.5, 156.2, 136.3, 136.2, 131.9, 131.6, 130.1, 128.9, 128.4,
127.5, 127.4, 114.3, 108.1, 92.3, 71.1, 68.1, 61.5, 56.4, 55.5.
HRMS (ESI) m/z: [M + H]+ calcd for C26H24O6 433.1651;
found, 433.1649.
(E ) - 7 - (Benzy loxy ) -3 - ( 3 ′ , 4 ′ -b i s (benzy loxy ) -
benzylidene)-5,8-dimethoxychroman-4-one (29c). To a
solution of 7-(benzyloxy)-5,8-dimethoxychroman-4-one (0.10
g, 0.32 mmol) in toluene (8 mL) were added 3,4-
bis(benzyloxy)benzaldehyde (0.15 g, 0.48 mmol) and p-
toluenesulfonic acid (6.2 mg, 0.04 mmol) at 0 °C. The
reaction mixture was refluxed for 13 h. After cooling to
ambient temperature, the mixture was concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/CH2Cl2
= 1:3:0.1) to afford (E)-7-(benzyloxy)-3-(3′,4′-bis(benzyloxy)-
benzylidene)-5,8-dimethoxychroman-4-one (29c) (0.10 g,
51%). 1H NMR (600 MHz, CDCl3) δ 7.69 (s, 1H), 7.46−
7.43 (m, 6H), 7.42−7.37 (m, 6H), 7.34−7.30 (m, 3H), 6.95
(d, 1H, J = 8.8 Hz), 6.84−6.82 (m, 2H), 6.19 (s, 1H), 5.22 (s,
2H), 5.21 (s, 2H) 5.18 (s, 2H), 5.15 (d, 2H, J = 1.6 Hz), 3.83
(s, 3H), 3.82 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3) δ
179.8, 158.1, 157.5, 156.1, 150.1, 148.6, 137.0, 136.8, 136.3,
136.1, 131.5, 130.4, 128.8, 128.7, 128.7, 128.4, 128.1, 128.1,
127.3, 127.3, 124.2, 116.9, 114.3, 107.9, 92.2, 71.5, 71.1, 71.0,
67.9, 61.4, 56.3. HRMS (ESI) m/z: [M + H]+ calcd for
C39H34O7 615.2383; found, 615.2379.
(E)-7-(Benzyloxy)-3-(3′-(benzyloxy)-4′-methoxyben-
zylidene)-5,8-dimethoxychroman-4-one (29d). To a
solution of 7-(benzyloxy)-5,8-dimethoxychroman-4-one (0.27
g, 0.87 mmol) in toluene (15 mL) were added 3-(benzyloxy)-
4-methoxybenzaldehyde (0.32 mg, 1.3 mmol) and p-
toluenesulfonic acid (14 mg, 0.09 mmol) at 0 °C. The
reaction mixture was refluxed for 13 h. After cooling to
ambient temperature, the mixture was concentrated under
reduced pressure. The residue was purified by flash column
chromatography on silica gel (ethyl acetate/n-hexane/CH2Cl2
= 1:1:0.1) to afford (E)-7-(benzyloxy)-3-(3′-(benzyloxy)-4′-
methoxybenzylidene)-5,8-dimethoxychroman-4-one (29d)
(0.26 g, 56%). 1H NMR (600 MHz, CDCl3) δ 7.69 (s, 1H),
7.46−7.43 (m, 4H), 7.41−7.38 (m, 4H), 7.36−7.30 (m, 2H),
6.93 (d, 1H, J = 8.4 Hz), 6.89 (dd, 1H, J = 8.4, 1.8 Hz), 6.79
(d, 1H, J = 1.8 Hz), 6.19 (s, 1H), 5.23 (s, 2H), 5.18 (s, 2H),
5.14 (d, 2H, J = 1.7 Hz), 3.94 (s, 3H), 3.84 (s, 3H), 3.82 (s,
3H). 13C{1H} NMR (150 MHz, CDCl3) δ 179.9, 158.2, 157.5,
156.2, 150.9, 148.0, 136.9, 136.3, 136.3, 131.6, 130.3, 128.9,
128.8, 128.4, 128.2, 127.6, 127.4, 127.3, 124.2, 115.9, 111.6,
108.0, 92.2, 71.3, 71.1, 67.9, 61.5, 56.4, 56.2. HRMS (ESI) m/
z: [M + H]+ calcd for C33H30O7 539.2070; found, 539.2071.
Punctatin (8). To a solution of (E)-7-(benzyloxy)-3-(4′-
(benzyloxy)benzylidene)-5,8-dimethoxychroman-4-one (29a)
(30 mg, 0.06 mmol) in CH2Cl2 (2 mL) was added boron
trichloride (0.18 mL, 1.0 M solution in CH2Cl2) at −78 °C.
After stirring for 1 h, the reaction mixture was diluted with
CH2Cl2, washed with water, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate/CH2Cl2 = 1:3) to afford punctatin (8) (9.1 mg, 49%).
1H NMR (600 MHz, DMSO-d6) δ 12.62 (s, 1H), 10.74 (br s,
1H), 10.17 (br s, 1H), 7.69 (s, 1H), 7.35 (d, 2H, J = 8.6 Hz),
6.89 (d, 2H, J = 8.6 Hz), 5.99 (s, 1H), 5.41 (d, 3H, J = 1.4
Hz), 3.63 (s, 3H). 13C{1H} NMR (150 MHz, DMSO-d6) δ
184.6, 160.1, 159.5, 159.5, 153.4, 136.9, 132.9, 128.3, 126.1,
124.7, 115.8, 101.8, 96.2, 67.4, 60.5. HRMS (ESI) m/z: [M +
H]+ calcd for C17H14O6 315.0869; found, 315.0865.
4′-O-Methylpunctatin (9). To a solution of (E)-7-
(benzyloxy)-5,8-dimethoxy-3-(4-methoxybenzylidene)-chro-
man-4-one (29b) (34 mg, 0.08 mmol) in CH2Cl2 (2 mL) was
added boron trichloride (0.25 mL, 1.0 M solution in CH2Cl2)
at −78 °C. After stirring for 1 h, the reaction mixture was
diluted with CH2Cl2, washed with water, dried over anhydrous
Na2SO4, and concentrated under reduced pressure. The
residue was purified by flash column chromatography on silica
gel (ethyl acetate/CH2Cl2 = 1:3) to afford 4′-O-methylpunc-
tatin (9) (11 mg, 42%). 1H NMR (600 MHz, DMSO-d6) δ
12.58 (s, 1H), 10.77 (br s, 1H), 7.73 (s, 1H), 7.45 (d, 2H, J =
8.7 Hz), 7.06 (d, 2H, J = 8.8 Hz), 5.99 (s, 1H), 5.41 (d, 2H, J
= 1.8 Hz), 3.83 (s, 3H), 3.63 (s, 3H). 13C{1H} NMR (150
MHz, DMSO-d6) δ 184.6, 160.7, 160.2, 159.6, 153.4, 136.4,
132.6, 128.4, 127.1, 126.2, 114.4, 101.9, 96.2, 67.4, 60.5, 55.4.
HRMS (ESI) m/z: [M + H]+ calcd for C18H16O6 329.1025;
found, 329.1025.
3-(3′,4′-Dihydroxybenzylidene)-5,7-dihydroxy-8-me-
thoxychroman-4-one (10). To a solution of (E)-7-
(benzyloxy)-3-(3,4-bis(benzyloxy)benzylidene)-5,8-dime-
thoxy-chroman-4-one (29c) (45 mg, 0.07 mmol) in CH2Cl2 (2
mL) was added boron trichloride (0.37 mL, 1.0 M solution in
CH2Cl2) at −78 °C. After stirring for 3 h, the reaction mixture
was diluted with CH2Cl2, washed with water, dried over
Na2SO4, and concentrated under reduced pressure. The
residue was purified by flash column chromatography on silica
gel (ethyl acetate/CH2Cl2 = 1:3) to afford 3-(3′,4′-
dihydroxybenzylidene)-5,7-dihydroxy-8-methoxychroman-4-
one (10) (14 mg, 60%). 1H NMR (600 MHz, CD3OD) δ
12.58 (s, 1H), 7.69 (s, 1H), 6.87 (d, 1H, J = 8.2 Hz), 6.84 (d,
1H, J = 2.0 Hz), 6.78 (dd, 1H, J = 8.2, 2.0 Hz), 5.96 (s, 1H),
5.39 (d, 2H, J = 1.7 Hz), 3.74 (s, 3H). 13C{1H} NMR (150
MHz, CD3OD) δ 186.6, 161.6, 161.2, 154.9, 149.1, 146.7,
138.8, 129.7, 128.0, 127.5, 124.8, 118.4, 116.6, 103.6, 97.3,
ACS Omega http://pubs.acs.org/journal/acsodf Article
https://dx.doi.org/10.1021/acsomega.0c00932
ACS Omega 2020, 5, 11043−11057
11054
69.0, 61.6. HRMS (ESI) m/z: [M + H]+ calcd for C17H14O7
331.0818; found, 331.0813.
7-Hydroxy-3-(4′-hydroxybenzyl)-5,8-dimethoxychro-
man-4-one (30). (E)-7-(Benzyloxy)-3-(4-(benzyloxy)-
benzylidene)-5,8-dimethoxychroman-4-one (29a) (21 mg,
0.04 mmol) and 10% Pd/C (1.5 mg, 0.01 mmol) in
methanol/dichloromethane (1 mL, 1 mL) were placed under
an atmosphere of hydrogen. After stirring for 3 h, the mixture
was filtered through a Celite pad. After the filtrate was
concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) afforded 7-hydroxy-3-(4′-hydroxyben-
zyl)-5,8-dimethoxychroman-4-one (30) (12 mg, 91%). 1H
NMR (600 MHz, CD3OD) δ 7.05 (d, 2H, J = 8.4 Hz), 6.73 (d,
2H, J = 8.4 Hz), 6.14 (s, 1H), 4.31 (dd, 1H, J = 11.3, 3.9 Hz),
4.16 (dd, 1H, J = 11.3, 6.6 Hz), 3.79 (s, 3H), 3.74 (s, 3H), 3.03
(dd, 1H, J = 13.3, 4.2 Hz), 2.70−2.66 (m, 1H), 2.63 (dd, 1H, J
= 13.3, 10.2 Hz). 13C{1H} NMR (150 MHz, CD3OD) δ 194.0,
159.7, 159.0, 158.1, 157.1, 131.2, 130.4, 116.4, 105.6, 94.1,
70.2, 61.4, 56.2, 49.8, 33.4. HRMS (ESI) m/z: [M + H]+ calcd
for C18H18O6 331.1181; found, 331.1181.
7-Hydroxy-3-(3′-hydroxy-4′-methoxybenzyl)-5,8-di-
methoxychroman-4-one (31). (E)-7-(Benzyloxy)-3-(3-
(benzyloxy)-4-methoxybenzylidene)-5,8-dimethoxychroman-
4-one (29d) (0.10 mg, 0.19 mmol) and 10% Pd/C (6.0 mg,
0.06 mmol) in methanol/dichloromethane (3 mL, 3 mL) were
placed under an atmosphere of hydrogen. After stirring for 1 h,
the mixture was filtered through a Celite pad. After the filtrate
was concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) afforded 7-hydroxy-3-(3′-hydroxy-4′-
methoxybenzyl)-5,8-dimethoxychroman-4-one (31) (67 mg,
98%). 1H NMR (600 MHz, CD3OD) δ 6.85 (d, 1H, J = 8.2
Hz), 6.71 (d, 1H, J = 2.0 Hz), 6.67 (dd, 1H, J = 8.2, 2.0 Hz),
6.14 (s, 1H), 4.31 (dd, 1H, J = 11.3, 4.0 Hz), 4.16 (dd, 1H, J =
11.3, 6.8 Hz), 3.82 (s, 3H), 3.79 (s, 3H), 3.74 (s, 3H), 3.01
(dd, 1H, J = 13.7, 4.6 Hz), 2.71−2.67 (m, 1H), 2.60 (dd, 1H, J
= 13.7, 10.3 Hz). 13C{1H} NMR (150 MHz, CD3OD) δ 193.9,
159.7, 159.1, 158.1, 147.8, 147.7, 132.6, 130.4, 121.4, 117.1,
112.9, 105.6, 94.1, 70.2, 61.4, 56.4, 56.2, 49.7, 33.6. HRMS
(ESI) m/z: [M + H]+ calcd for C19H20O7 361.1287; found,
361.1284.
(E)-3-(4′-Hydroxybenzylidene)-5,7,8-trimethoxychro-
man-4-one (32a). 1H NMR (600 MHz, CDCl3) δ 7.79 (s,
1H), 7.19 (d, 2H, J = 8.3 Hz), 6.94 (d, 2H, J = 8.3 Hz), 6.45
(s, 1H), 6.17 (s, 1H), 5.30 (s, 2H), 3.95 (s, 3H), 3.92 (s, 3H),
3.79 (s, 3H). 13C{1H} NMR (150 MHz, CDCl3) δ 180.4,
158.7, 158.7, 157.5, 156.1, 136.8, 132.1, 131.0, 129.7, 127.1,
116.0, 107.6, 90.1, 68.0, 61.5, 56.4, 56.2.
(E)-7-Hydroxy-3-(4′-hydroxybenzylidene)-5,8-dime-
thoxychroman-4-one (32b). 1H NMR (600 MHz, CD3OD)
δ 7.71 (s, 1H), 7.24 (d, 2H, J = 8.5 Hz), 6.88 (d, 2H, J = 8.5
Hz), 6.20 (s, 1H), 5.30 (d, 2H, J = 1.7 Hz), 3.82 (s, 3H), 3.75
(s, 3H). 13C{1H} NMR (150 MHz, CD3OD) δ 180.4, 159.0,
158.5, 157.6, 156.3, 136.3, 131.9, 129.4, 129.2, 125.8, 115.3,
106.0, 93.4, 67.5, 60.2, 54.8.
( E ) - 7 - H y d r o x y - 5 , 8 - d i m e t h o x y - 3 - ( 4 ′ -
methoxybenzylidene)chroman-4-one (32c). 1H NMR
(600 MHz, DMSO-d6) δ 10.39 (s, 1H), 7.55 (s, 1H), 7.38
(d, 2H, J = 8.8 Hz), 7.03 (d, 2H, J = 8.8 Hz), 6.20 (s, 1H),
5.27 (d, 2H, J = 1.6 Hz), 3.82 (s, 3H), 3.73 (s, 3H), 3.63 (s,
3H). 13C{1H} NMR (150 MHz, DMSO-d6) δ 177.9, 160.1,
157.5, 156.8, 155.9, 134.1, 132.0, 130.3, 129.3, 126.7, 114.3,
106.1, 94.2, 67.5, 60.6, 55.7, 55.3.
3-(4′-(Benzyloxy)benzyl)-5-hydroxy-7,8-dimethoxy-
chroman-4-one (33a). 1H NMR (600 MHz, CDCl3) δ 12.06
(s, 1H), 7.44 (d, 2H, J = 7.5 Hz), 7.39 (t, 2H, J = 7.5 Hz), 7.33
(t, 1H, J = 7.3 Hz), 7.16 (d, 2H, J = 8.6 Hz), 6.94 (d, 2H, J =
8.6 Hz), 6.11 (s, 1H), 5.06 (s, 2H), 4.36 (dd, 1H, J = 11.5, 4.2
Hz), 4.21 (dd, 1H, J = 11.5, 7.1 Hz), 3.89 (s, 3H), 3.78 (s,
3H), 3.18 (dd, 1H, J = 14.0, 4.5 Hz), 2.85 (m, 1H), 2.74 (dd,
1H, J = 14.0, 10.3 Hz). 13C{1H} NMR (150 MHz, CDCl3) δ
198.3, 161.4, 160.4, 157.8, 153.8, 137.1, 130.3, 130.1, 129.5,
128.7, 128.1, 127.6, 115.2, 102.5, 93.1, 70.2, 69.5, 61.5, 56.4,
47.1, 32.1.
3-(3′,4′-Bis(benzyloxy)benzyl)-5-hydroxy-7,8-dime-
thoxychroman-4-one (33b). 1H NMR (600 MHz, CDCl3)
δ 12.04 (s, 1H), 7.44 (d, 4H, J = 7.7 Hz), 7.36 (td, 4H, J = 7.4,
4.1 Hz), 7.30 (dd, 2H, J = 14.3, 7.1 Hz), 6.88 (d, 1H, J = 8.2
Hz), 6.80 (d, 1H, J = 2.0 Hz), 6.74 (dd, 1H, J = 8.2, 2.0 Hz),
6.10 (s, 1H), 5.15 (d, 4H, J = 4.9 Hz), 4.27 (dd, 1H, J = 11.5,
4.2 Hz), 4.09 (dd, 1H, J = 11.5, 7.3 Hz), 3.89 (s, 3H), 3.77 (s,
3H), 3.12 (dd, 1H, J = 14.0, 4.4 Hz), 2.79 (m, 1H), 2.68 (dd,
1H, J = 14.0, 10.2 Hz).
3-(3′-(Benzyloxy)-4′-methoxybenzyl)-5-hydroxy-7,8-
dimethoxychroman-4-one (33c). 1H NMR (600 MHz,
CDCl3) δ 12.04 (s, 1H), 7.43 (d, 2H, J = 7.5 Hz), 7.36 (t, 2H,
J = 7.6 Hz), 7.29 (t, 1H, J = 7.4 Hz), 6.84 (d, 1H, J = 8.1 Hz),
6.78 (dd, 1H, J = 8.1, 1.9 Hz), 6.75 (d, 1H, J = 1.9 Hz), 6.10
(s, 1H), 5.14 (s, 2H), 4.27 (dd, 1H, J = 11.5, 4.2 Hz), 4.09 (dd,
1H, J = 11.5, 7.3 Hz), 3.89 (s, 3H), 3.88 (s, 3H), 3.78 (s, 3H),
3.11 (dd, 1H, J = 13.9, 4.4 Hz), 2.78 (m, 1H), 2.69 (dd, 1H, J
= 13.9, 10.1 Hz). 13C{1H} NMR (150 MHz, CDCl3) δ 198.2,
161.5, 160.4, 153.8, 148.8, 148.2, 137.1, 130.2, 129.5, 128.7,
128.0, 127.5, 122.1, 115.4, 112.1, 102.5, 93.1, 71.2, 69.4, 61.5,
56.4, 56.2, 46.9, 32.4.
3-(3′-Hydroxy-4′-methoxybenzyl)-5,7,8-trimethoxy-
chroman-4-one (33d). 1H NMR (600 MHz, CDCl3) δ 6.81
(s, 1H), 6.78 (d, 1H, J = 8.1 Hz), 6.71 (d, 1H, J = 8.1 Hz),
6.12 (s, 1H), 5.59 (s, 1H), 4.35 (dd, 1H, J = 11.2, 3.6 Hz), 4.18
(dd, 1H, J = 10.8, 8.0 Hz), 3.94 (s, 3H), 3.92 (s, 3H), 3.87 (s,
3H), 3.79 (s, 3H), 3.18 (dd, J = 14.0, 4.0 Hz, 1H), 2.78 (m,
1H), 2.58 (dd, J = 14.0, 10.5 Hz, 1H). 13C{1H} NMR (150
MHz, CDCl3) δ 191.6, 158.5, 158.2, 156.3, 145.6, 145.3, 131.8,
130.6, 120.6, 115.2, 110.8, 105.7, 89.2, 69.3, 61.2, 56.2, 56.1,
56.0, 48.5, 32.1.
3,9-Dihydropunctatin (11). To a solution of 7-hydroxy-3-
(4′-hydroxybenzyl)-5,8-dimethoxy-chroman-4-one (30) (17
mg, 0.05 mmol) in CH2Cl2 (2 mL) was added boron
trichloride (0.15 mL, 1.0 M solution in CH2Cl2) at −78 °C.
After stirring for 2 h, the reaction mixture was diluted with
CH2Cl2, washed with water, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) to afford 3,9-dihydropunctatin (11)
(8.0 mg, 50%). 1H NMR (600 MHz, DMSO-d6) δ 11.96 (s,
1H), 10.68 (s, 1H), 9.26 (s, 1H), 7.03 (d, 2H, J = 8.4 Hz), 6.69
(d, 2H, J = 8.4 Hz), 5.94 (s, 1H), 4.31 (dd, 1H, J = 11.3, 4.4
Hz), 4.13 (dd, 1H, J = 11.4, 7.9 Hz), 3.60 (s, 3H), 3.00 (dd,
1H, J = 13.7, 5.0 Hz), 2.98−2.93 (m, 1H), 2.61 (dd, 1H, J =
13.7, 9.3 Hz). 13C{1H} NMR (150 MHz, DMSO-d6) δ 198.0,
159.8, 158.8, 155.9, 154.3, 130.0, 128.2, 128.0, 115.2, 101.3,
95.9, 69.1, 60.4, 45.6, 31.2. HRMS (ESI) m/z: [M + H]+ calcd
for C17H16O6 317.1025; found, 317.1019.
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5,6-Dihydroxy-3-(3′-hydroxy-4′-methoxybenzyl)-8-
methoxychroman-4-one (12). To a solution of 7-hydroxy-
3-(3′-hydroxy-4′-methoxybenzyl)-5,8-dimethoxy-chroman-4-
one (31) (20 mg, 0.05 mmol) in CH2Cl2 (2 mL) was added
boron trichloride (0.16 mL, 1.0 M solution in CH2Cl2) at −78
°C. After stirring for 3 h, the reaction mixture was diluted with
CH2Cl2, washed with water, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) to afford 5,6-dihydroxy-3-(3′-hydroxy-
4′-methoxybenzyl)-8-methoxychroman-4-one (12) (8.1 mg,
42%). 1H NMR (600 MHz, CD3OD) δ 6.86 (d, 1H, J = 8.2
Hz), 6.72 (d, 1H, J = 2.1 Hz), 6.68 (dd, 1H, J = 8.2, 2.1 Hz),
5.94 (s, 1H), 4.33 (dd, 1H, J = 11.4, 4.3 Hz), 4.17 (dd, 1H, J =
11.4, 7.2 Hz), 3.83 (s, 3H), 3.73 (s, 3H), 3.08 (dd, 1H, J =
13.9, 4.7 Hz), 2.86−2.82 (m, 1H), 2.65 (dd, 1H, J = 13.9, 10.2
Hz). 13C{1H} NMR (150 MHz, CD3OD) δ 199.5, 161.1,
161.1, 155.7, 147.9, 147.7, 132.2, 129.6, 121.4, 117.1, 112.9,
102.9, 97.0, 70.6, 61.5, 56.4, 47.9, 33.2. HRMS (ESI) m/z: [M
+ H]+ calcd for C18H18O7 347.1131; found, 347.1125.
3-(4-Hydroxybenzyl)-5,8-dimethoxychroman-7-ol
(14). (E)-7-(Benzyloxy)-3-(4-(benzyloxy)benzylidene)-5,8-di-
methoxychroman-4-one (29a) (30 mg, 0.06 mmol), and 10%
Pd/C (1.8 mg, 0.006 mmol) in methanol (2 mL) were placed
under an atmosphere of hydrogen. After stirring for 3 h, the
mixture was filtered through a Celite pad. After the filtrate was
concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) afforded 3-(4-hydroxybenzyl)-5,8-
dimethoxychroman-7-ol (14) (17 mg, 93%). 1H NMR (600
MHz, CD3OD) δ 7.01 (d, 2H, J = 8.5 Hz), 6.72 (d, 2H, J = 8.5
Hz), 6.03 (s, 1H), 4.11 (ddd, 1H, J = 10.5, 3.0, 1.5 Hz), 3.71−
3.69 (m, 4H), 3.68 (s, 3H), 2.61 (ddd, 1H, J = 16.3, 5.4, 1.5
Hz), 2.58−2.49 (m, 2H), 2.18 (dd, 1H, J = 16.3, 8.5 Hz),
2.14−2.07 (m, 1H). 13C{1H} NMR (150 MHz, CD3OD) δ
156.8, 155.1, 149.6, 149.4, 131.7, 131.0, 130.8, 116.2, 103.8,
92.4, 70.78, 61.2, 55.8, 38.2, 35.2, 26.2. HRMS (ESI) m/z: [M
+ H]+ calcd for C18H20O5 317.1389; found, 317.1386.
3-(4-Hydroxybenzyl)-7,8-dimethoxychroman-5-ol
(34). 7-O-Methoxypunctatin (2) (10 mg, 0.03 mmol) and 10%
Pd/C (1.4 mg, 0.01 mmol) in methanol (2 mL) were placed
under an atmosphere of hydrogen. After stirring for 24 h, the
mixture was filtered through a Celite pad. After the filtrate was
concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) afforded 3-(4-hydroxybenzyl)-7,8-
dimethoxychroman-5-ol (34) (3.4 mg, 35%). 1H NMR (600
MHz, CD3OD) δ 7.03 (d, 2H, J = 8.4 Hz), 6.73 (d, 2H, J = 8.4
Hz), 6.06 (s, 1H), 4.13 (ddd, 1H, J = 10.4, 2.7, 1.2 Hz), 3.75
(s, 3H), 3.76−3.71 (m, 1H), 3.67 (s, 3H), 2.67 (ddd, 1H, J =
16.3, 5.4, 1.1 Hz), 2.56 (m, 2H), 2.24 (dd, 1H, J = 16.3, 8.5
Hz), 2.16−2.09 (m, 1H). 13C{1H} NMR (150 MHz, CD3OD)
δ 156.6, 152.3, 152.2, 149.6, 131.5, 131.1, 130.8, 115.9, 103.8,
92.9, 70.6, 61.1, 56.1, 38.0, 35.0, 26.2.
3-(4-Hydroxybenzyl)-5,7-dimethoxychroman-8-ol
(36). First step: (E)-3-(4-(benzyloxy)benzylidene)-5,7,8-tri-
methoxychroman-4-one (19a) (0.15 g, 0.35 mmol) and 10%
Pd/C (14 mg, 0.13 mmol) in methanol (6 mL) were placed
under an atmosphere of hydrogen. After stirring for 24 h, the
mixture was filtered through a Celite pad. After the filtrate was
concentrated under reduced pressure, purification of the
residue via flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) afforded 4-((5,7,8-trimethoxychro-
man-3-yl)methyl)phenol (35) (0.10 g, 90%). 1H NMR (600
MHz, CDCl3) δ 7.05 (d, 2H, J = 8.2 Hz), 6.77 (d, 2H, J = 8.5
Hz), 6.09 (s, 1H), 5.07 (br s, 1H), 4.21 (ddd, 1H, J = 10.5, 3.0,
1.6 Hz), 3.86 (s, 3H), 3.79 (s, 3H), 3.79−3.74 (m, 4H), 2.72
(ddd, 1H, J = 16.3, 5.3, 1.6 Hz), 2.59 (d, 2H, J = 7.2 Hz), 2.26
(dd 1H, J = 16.3, 8.6 Hz,), 2.23−2.16 (m, 1H). 13C{1H} NMR
(150 MHz, CDCl3) δ 154.2, 153.6, 151.4, 148.9, 131.6, 130.2,
115.4, 104.4, 88.9, 70.0, 61.2, 56.5, 55.7, 37.5, 33.7, 25.5.
HRMS (ESI) m/z: [M + H]+ calcd for C19H22O5 331.1545;
found, 331.1540. Second step: To a solution of 4-((5,7,8-
trimethoxychroman-3-yl)methyl)phenol (35) (0.10 g, 0.31
mmol) in CH2Cl2 (3 mL) was added boron trichloride (1.0
mL, 1.0 M solution in CH2Cl2) at 0 °C. After stirring for 3 h at
ambient temperature, the reaction mixture was diluted with
CH2Cl2, washed with water, dried over anhydrous Na2SO4,
and concentrated under reduced pressure. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate/n-hexane = 1:1) to afford 3-(4-hydroxybenzyl)-5,7-
dimethoxychroman-8-ol (36) (67 mg, 68%). 1H NMR (600
MHz, CD3OD) δ 7.02 (d, 2H, J = 8.4 Hz), 6.72 (d, 2H, J = 8.4
Hz), 6.20 (s, 1H), 4.15 (ddd, 1H, J = 10.5, 2.9, 1.5 Hz), 3.82
(s, 3H), 3.73 (s, 3H), 3.75−3.70 (m, 1H), 2.66 (ddd, 1H, J =
16.5, 5.4, 1.3 Hz), 2.58−2.52 (m, 2H), 2.22 (dd, 1H, J = 16.5,
8.7 Hz), 2.12 (m, 1H). 13C{1H} NMR (150 MHz, CD3OD) δ
156.8, 151.7, 147.2, 144.9, 131.7, 131.0, 129.6, 116.2, 105.4,
90.6, 70.9, 57.0, 56.2, 38.3, 35.3, 26.3.
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